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1. Introduction
Undisclosing  the  sequence  of  the  human  genome  was  finished  in  principle  in  2003
(Schmutz  et al., 2004). Since then, the challenge for science is not only elucidating the
position  and  structure  of  the  genes  in  the  succession  of  the  base  pairs,  but  rather
understanding the role of  each of these genes in the complex interplay in the cellular
network  of  the  human  body.  In  this  thesis  two  genes,  thyroid  adenoma  associated
(THADA) and high-mobility group A2 (HMGA2), were analyzed mainly in context with their
expression in dedifferentiated and extra-embryonic human tissues.
THADA (thyroid adenoma associated), located on the short arm of chromosome 2, was
discovered by Rippe et al. (2003) as the target gene involved in translocations commonly
found  in  thyroid  adenomas. Besides polysomy  7  and  19q13  aberrations,  2p21
rearrangements were identified as the third most frequent mutation in hyperplasias and
benign follicular tumors of the thyroid (Bondeson et al., 1989; Teyssier et al., 1990; Dal Cin
et al.,  1992;  Belge  et al.,  1994;  Belge  et al.,  1998;  Bol  et al.,  1999).  Identification  of
THADA became possible after the breakpoint was narrowed down to a region of 450 kbp
(Bol et al., 2001).
Except  for  one entry  in  the  GenBank  database  by  Puduvalli  and  Ridgway  (GenBank
accession reference note), describing an interaction of THADA with death receptor DR5 in
a two-hybrid experiment, no information about its function was available prior to this work.
In  conjunction  with  the  studies  presented  in  this  thesis,  research  by Drieschner  et al.
(2007),  analyzing  the  structure  of  THADA in  several  vertebrates  (Canis  familiaris,
Chlorocebus aethiops,  Gallus gallus,  and  Mus musculus),  revealed similarities to  ARM
repeat  structures.  Also  identified  was  the  most  conserved  part  of  the  protein
(aa 1033 - 1415  Homo sapiens) hinting at a putative important functional domain. 2p21
translocations, resulting in truncations of THADA, disrupt this domain. This might cause a
loss of function contributing to the development of the above mentioned follicular thyroid
neoplasias (Drieschner et al., 2007).
Drieschner  et al.  (2006) also reported a follicular thyroid adenoma with  a translocation
t(2;20;3)(p21;q11.2;p25), which showed an intronic sequence of PPARγ fused to exon 28
of  THADA. The authors concluded that the close surrounding of  PPARγ is likely to be a
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breakpoint hot spot region, which leads to recurrent alterations of this gene in follicular
thyroid neoplasias with or without the involvement of PAX8 (Drieschner et al., 2006).
Nikiforov  et al.  (2014)  used  next-generation  sequencing  (NGS)  on  143  fine-needle
aspirations (FNA) of thyroid nodules. By applying a panel with simultaneous testing for
point mutations in 13 genes and for 42 types of gene fusions that occur in thyroid cancer,
in five cases a fusion gene involving THADA and IGF2BP3 as the unique diagnostic event
was  detected  (Nikiforov  et al.,  2014).  The  authors  concluded  that  comprehensive
genotyping  of  thyroid  nodules  using  a  broad  NGS panel  should  facilitate  the  optimal
management of patients with indeterminate diagnosis after an FNA.
In a study investigating a t(2;11)(p21;q23) mutation in 19 myelodysplastic syndrome (MDS)
and acute myeloid leukemia (AML) cases (Bousquet et al., 2008), THADA expression was
measured due to its location close to the breakpoint. No difference in expression level
could  be  detected  for  the  THADA mRNA,  the  authors  deemed  the  upregulation  of
miR-125b-1 to represent a new mechanism of myeloid cell transformation. An involvement
of  THADA in a translocation t(2;3)(p15-21;q26-27) in two AML patients was detected by
Trubia et al. (2006). Since the orientation of THADA was opposite to the one of its fusion
partner,  a contribution to a fusion protein was deemed unlikely by the authors (Trubia
et al., 2006).
Additionally,  THADA has been associated with several diseases, namely type 2 diabetes
(T2D) (Zeggini  et al., 2008), polycystic ovary syndrome (PCOS) (Chen  et al., 2011), and
nonsyndromic cleft lip  (Ludwig et al., 2012).  Zeggini  et al. carried out a meta analysis of
three  genome-wide  association  studies  (GWAS)  investigating  about  2.2 million  single
nucleotide polymorphisms (SNP) in more than 10,000 individuals of European descent for
a possible association with T2D. A THADA allele characterized by a SNP in exon 24 turned
out to be significantly associated with an elevated risk of developing T2D (Zeggini  et al.,
2008).  These  initial  findings  were  corroborated by several  other  investigations  (Parikh
et al., 2009; Simonis-Bik  et al., 2010; Voight  et al., 2010; Gupta  et al., 2012; Nitert  et al.,
2012;  Franceschini  et al.,  2013;  Ho  et al.,  2013;  Pendse  et al.,  2013).  The  same
association found in a European cohort as described in Zeggini et al. (2008) was detected
in Indian sib pairs by Gupta  et al. (2012) and in American Indians by Franceschini  et al.
(2013).  An association between  THADA risk allele and ß-cell  mass (Simonis-Bik  et al.,
2010),  and  function  (Voight  et al.,  2010)  was  reported.  Other  investigations  found
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differences in methylation status (Nitert  et al.,  2012) and expression level of  THADA in
ß cells  in  pancreatic  islets  in  humans  (Parikh  et al.,  2009)  and  adipose  tissue  and
pancreatic islets in mice (Ho et al., 2013) in relation to T2D. Nevertheless, in a substantial
amount of studies no correlation of  THADA with T2D could be detected (Grarup  et al.,
2008;  Staiger  et al.,  2008;  Boesgaard  et al.,  2009;  Sanghera  et al.,  2009;  Stančáková
et al., 2009; Vangipurapu  et al., 2011; Almawi  et al., 2013). No correlation was found for
the  THADA risk variant for obesity,  insulin secretion and insulin sensitivity in a Danish
(Grarup  et al.,  2008),  and a German (Staiger  et al.,  2008)  cohort.  The same negative
results  for the insulin  related T2D traits  were observed in studies testing Finnish men
(Stančáková et al., 2009), European individuals (Boesgaard et al., 2009) and Asian Indian
Sikhs (Sanghera et al., 2009). In a case-control association study with Lebanese-Arabs no
association  between  THADA risk  allele  and  T2D  was  found  (Almawi  et al.,  2013).  In
several  cases authors suggest that their  negative findings may be explained by a low
statistical power, i.e. an insufficient study size relative to the allele frequency (Grarup et al.,
2008; Sanghera  et al., 2009; Stančáková  et al., 2009; Almawi  et al., 2013). In one case,
because of an extremely low minor allele frequency,  THADA was excluded from a study
(Kang  et al.,  2009).  Additionally,  two  studies  tested  if  THADA can  have  an  indirect
influence on diabetes (Zhao et al., 2010; Hotta et al., 2012), but the former study did not
reveal a correlation between higher pediatric body mass index, a known risk factor in the
development  of  T2D  in  later  life,  and  a  THADA risk  variant. Hotta  et al.  genotyped
Japanese individuals to examine T2D susceptibility loci, including THADA, and visceral fat
accumulation,  which  has  an  important  role  in  the  development  of  several  metabolic
disorders, like T2D,  but found none. Also, no association between  THADA and type 1
diabetes was reported by Raj et al. (2009).
Patients  with  diabetes  mellitus  carry an  increased risk  of  developing  colon  and rectal
cancer (Larsson et al., 2005). In a case-control study by Cheng et al. (2011) testing known
risk  alleles  of  T2D,  THADA rs7578597  Thr1187Ala  missense  polymorphism  had  the
strongest association for colon cancer, but the low risk allele for T2D turned out to be the
high  risk  variant  for  colon  cancer.  Congruously,  the  authors  suggested  a  different
mechanism for  each  disease,  driven  by  different  biological  effects  of  THADA and  its
variants, respectively.
PCOS is a very common chronic endocrine disorder, affecting up to 20 % of females in
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reproductive age (Teede et al., 2010). An association between PCOS and three SNP-loci
in  THADA ORF  was  first  reported  by  Chen  et al.  (2011),  investigating  Han  Chinese
individuals. These results were corroborated in a family-based analysis on the same ethnic
group  (Zhao  et al.,  2012).  This  association  was  also  found  in  a  European  derived
(Goodarzi et al., 2012), and a Dutch (Louwers et al., 2013) cohort. Despite the confirmed
relation between genotype and PCOS, Goodarzi et al. could not find a correlation between
SNPs and PCOS traits like testosterone levels. Contradictory to these results, Cui  et al.
(2013)  reported  a  correlation  between  SNPs  located  in  THADA and  increased
testosterone, among other traits. Other studies failed to find any correlation (Lerchbaum
et al., 2011; Eriksen  et al., 2012; Wang  et al., 2012; Welt  et al., 2012). Lerchbaum  et al.
tested rs13429458, one of the risk alleles of THADA reported by Chen et al. (2011), in a
Caucasian  cohort;  Eriksen  et al.  (2012)  investigated  the  same  variant  in  Danish
descendants with PCOS or hirsutism. In both cases the genotype distribution and allele
frequency as well  as the endocrine or metabolic parameters did not differ  significantly
between patient and control groups. Wang et al. (2012) conducted a case-control study on
Han Chinese women with endometrial carcinomas but found no statistical difference for
rs13429458. A study testing all  three SNPs located in  THADA on women of European
ancestry performed by Welt et al. (2012) revealed no association with PCOS, but for one
of the alleles testosterone levels were higher. The authors suggested a possible ethnic
specificity (Welt et al., 2012). Contrary to this, Brower et al. (2014) concluded that THADA
loci are likely to play important roles in PCOS across populations.
PCOS can lead to insulin resistance and T2D (Wild  et al.,  2000; Carmina  et al.,  2009;
Teede  et al.,  2010). A study conducted on women of European ancestry tested for the
possibly  T2D  associated  THADA  SNP rs7578597  in  correlation  to  PCOS,  but  no
association could be detected (Saxena, Welt, 2013). The authors also reported no linkage
disequilibrium (LD) between the possible T2D alleles with the PCOS variants (Saxena,
Welt, 2013), corroborating the results reported by Goodarzi et al. (2012), and partly those
of Chen et al. (2011), who in addition found such an LD in a cohort consisting of residents
of Utah, USA, with Northern and Western European ancestries, opposite to those of a Han
Chinese cohort.
THADA in correlation with nonsyndromic cleft lip with or without cleft palate (NSCL/P) was
first mentioned in a GWAS testing individuals of central European origin by Mangold et al.
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(2010). But the association of rs7590268, located in intron 31 of  THADA,  and NSCL/P
turned out to be not significant (Mangold et al., 2010). Later, this association was reported
as being significant by Ludwig et al. (2012), who conducted a meta-analysis of the GWAS
mentioned in Mangold et al. and one presented in Beaty et al. (2010), which consisted of
case-parent  trios  of  European  and  Asian  ancestry.  While  rs7590268  achieved  no
significance in a replication study by Beaty et al. (2013), several nearby SNPs did. A case-
control study of a Chinese Han cohort by Pan et al. (2013) confirmed the association of
THADA and NSCL/P and elucidated an association between rs7590268 and a positive
family history of NSCL/P.
THADA was also mentioned in correlation with multiple sclerosis (MS) (Patsopoulos et al.,
2011).  In  a  meta-analysis  of  GWA studies  searching  for  SNPs  associated  with  MS,
rs6718520, located about 132 kbp away from THADA, was one of three newly discovered
SNPs.
A THADA variant has also been associated with elevated risk of cancer. In a large scale
GWAS  with  each  more  than  20,000  patients  and  controls,  Eeles et al.  (2009) found
THADA SNP rs1465618 to be highly significantly associated with prostate cancer. This
correlation  was  later  verified  by  Lindstrom et al.  (2011),  even  though  no  association
between this variant of  THADA and Gleason score and stage of the disease could be
detected. No correlation at all  for rs1465618 was found in a study restricted to African
American men (Haiman et al., 2011). In a study solely investigating this SNP, Zhao et al.
(2014) found a significant association with prostate cancer risk and aggressiveness in a
Chinese population.
While the majority of studies investigated THADA in humans, Soller et al. (2008) reported
the successful  mapping of  THADA in  the canine genome to chromosome 10p25.  The
authors argued that this region is not a hotspot for mutations in thyroid adenomas of the
dog.
In  opposite  to  THADA,  a  significantly  larger  amount  of  research  had  already  been
undertaken on  high-mobility group A2 (HMGA2).  Human HMGA2 was first detected by
Giancotti et al. (1991) in a hepatoma cell line. It belongs to a protein family of three main
subgroups. All are characterized by a small size of around 100 to 200 aa (Thomas, 2001;
Cleynen, Van de Ven, 2008; Pogna et al., 2010), and a high percentage of charged amino
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residues (Cleynen,  Van de Ven,  2008).  HMG proteins are highly abundant  non-histone
chromosomal proteins (Pogna et al., 2010). Members of the HMGN subfamily contain a
nucleosome binding domain (Rochman et al., 2010), HMGB proteins are characterized by
a  HMG-box  motif  (Thomas,  2001).  The  HMGA  subgroup  consists  of  four  proteins,
HMGA1a, HMGA1b, HMGA1c (deriving from alternative splicing of one transcript),  and
HMGA2,  these  are  encoded  by  two  genes.  All  HMGA proteins  contain  a  functional
sequence motif, the AT-hook, which enables them to bind to specific DNA or chromatin
structures (Cleynen, Van de Ven, 2008). Three AT-hooks are separately encoded in the
first three exons, exon IV contains the sequence for a spacer region of eleven amino acids
missing in HMGA1 (Chau et al., 1995). For all HMGA members, exon V encodes the acidic
tail (Chau et al., 1995). Due to diverging donor and acceptor splice sites and a different
stop  codon,  the  3'-part  of  HMGA1c differs  significantly  from the  other  HMGA-proteins
(Cleynen, Van de Ven, 2008). The acidic part of the protein is thought to be responsible for
modulation of interactions with other proteins (Noro et al., 2003). This reciprocation can
lead to  the  formation  of  complex molecular  aggregates  called  transcription  complexes
(Cleynen,  Van de Ven,  2008).  Protein-protein-interactions  involve  HMGA  in  several
molecular networks (reviewed in Sgarra et al., 2010). HMGA proteins have only very little
secondary structure when in solution but if bound to DNA or other proteins a transition to
ordered structure takes place (reviewed in Reeves, 2001). They belong to the most highly
adducted proteins of the nucleus, posttranscriptional  modifications can severely impact
their affinity to bind to other proteins and DNA (Cleynen, Van de Ven, 2008; Zhang, Wang,
2008).
Studies on knock-out mice showed that HMGA2 plays a crucial role in early development,
a null mutant genotype resulted in the pygmy phenotype (Zhou et al., 1995). Hirning-Folz
et al. (1998) found high expression throughout murine embryos at an early developmental
stage with a correlation between the expression of  HMGA2 and high proliferative tissue
activity.
HMGA2 is  downregulated in  adult  tissues (Rogalla et al.,  1996),  with  the exception  of
spermatocytes  and  spermatides  in  testis  (Kloth,  Gottlieb,  et al., 2015).  Reexpression,
truncation or generation of fusion transcripts through rearrangements is frequently found in
several benign tumors, like lipomas and uterine leiomyomas (reviewed in Fedele, Fusco,
2010).  Located in the chromosomal region 12q14-15 in humans,  HMGA2 is  frequently
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involved in translocations in benign neoplasias. In these cases the mutations often occur in
the very large third intron (Schoenmakers et al., 1995; Mine et al., 2001). This causes a
separation of the AT-hooks from the acidic tail resulting in a fusion protein with ectopic
sequences added to the DNA-binding section of HMGA2. In lipomas, a fusion with part of
LPP (LIM domain containing preferred translocation partner in lipoma) has been reported
(Petit et al., 1996). In this case the two most carboxyterminal LIM-domains from LPP are
fused to the three AT-hooks from HMGA2, thus creating an aberrant transcription factor
likely  contributing  to  lipomagenesis  (Crombez et al.,  2005).  In  uterine  leiomyomas,  a
different  pathological  mechanism  was proposed  as  translocation  breakpoints  were
detected  outside  of  HMGA2,  indicating  a  dysregulation  of  HMGA2 without  a  fusion
transcript (Schoenberg Fejzo et al., 1996). In concordance with these results, Quade et al.
(2003) deemed a fusion of  HMGA2 with the preferential translocation partner  RAD51L1
unnecessary for the development of this type of benign tumor. In the majority of other
cases involving a fusion gene, only a few in-frame amino acids or out-of frame sequences
are  added  to  the  truncated  HMGA2  (Cleynen,  Van de Ven,  2008),  suggesting  another
mechanism contributing to or initializing tumor development.
HMGA2 turned out to be a major target for let-7 miRNA (Boyerinas et al., 2008), multiple
target sites in the 3'-UTR of  HMGA2 mRNA were found (Lee, Dutta, 2007). Mayr et al.
(2007) proposed that by repressing  HMGA2, let-7 acts as a tumor suppressor gene and
that  in  various  human  tumors  the  loss  of  let-7  repression  is  a  major  mechanism  of
oncogenic  HMGA2 translocations.  Rearrangements  of  HMGA2 are  primarily  but  not
exclusively found in benign tumors. Tallini et al. (1997) detected the activation of HMGA2
through  cytogenetic  amplifications  in  malignant  atypical  lipomatous  tumors  (ALT),
Kazmierczak et al. (1999) reported a case of an inflammatory myofibroblastic tumor (IMT)
with an intragenic rearrangement. High expression of HMGA is mainly found in malignant
tumors  (reviewed  in  Cleynen,  Van de Ven,  2008;  Fedele,  Fusco,  2010).  This
overexpression can induce oncogenic transformation of the affected cell through several
mechanisms (Fedele, Fusco, 2010). By upregulation of proteins involved in the control of
the cell  cycle like E2F1, cyclinA, and CCNB2,  HMGA2 overexpression can lead to the
activation of the cell cycle (reviewed in Fedele, Fusco, 2010). HMGA proteins can also
influence  the  transformation  through  inhibition  of  DNA repair.  Borrmann et al.  (2003)
elucidated the downregulation of ERCC1, a protein involved in the nucleotide excision
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repair, by high expression of  HMGA2. For  HMGA1, several target genes participating in
double-strand break repair,  homologous recombination,  and base excision  repair  have
been reported (reviewed in  Reeves,  Adair,  2005).  Epithelial  to  mesenchymal  transition
(EMT) is a key event in embryogenesis, because in its absence development stops at the
gastrula stage due to lack of transformation of epithelial cells to the motile and unpolarized
mesenchymal  counterparts (reviewed  in  Thiery,  Sleeman,  2006).  EMT takes  place  in
numerous  stages  during  developmental  morphogenesis  (reviewed  in  Nakaya,  Sheng,
2013).  This  is  also  the  case  for  extra-embryonic  tissues.  The  change  of  the  villous
cytotrophoblast from a coherently layered alignment to an extravillous state through EMT
to enable a fetalomaternal exchange is of critical importance for a successful pregnancy
(Vićovac, Aplin, 1996; Kokkinos et al.,  2010).  In tumorigenesis this latent developmental
program  becomes  reactivated,  multiple  signaling  pathways  can  contribute  to  EMT
(reviewed in Huber et al.,  2005).  Thuault et al.  (2006; 2008) elucidated that  HMGA2 is
necessary and sufficient for transforming growth factor-beta (TGF-ß)-induced EMT. The
authors  outlined an EMT inducing pathway in which  HMGA2 gets indirectly activated by
TGF-ß and consequently, through  gene-specific regulation of the expression of SNAIL1,
leads to severe E-cadherin suppression and the EMT phenotype (Thuault et al.,  2008).
HMGA2 has  been  suggested  as  a  therapeutic  target  in  pancreatic  cancer,  a  highly
malignant neoplasia due to elevated mitotic activity and EMT (Watanabe et al.,  2009).  At
the invasive front of a tumor, a one-cell-thick layer of dedifferentiated and incoherent cells
can be found (Morishita et al.,  2013).  In  several  tumor  types  HMGA2 expression  was
detected at this  layer (Morishita et al.,  2013). The authors reported the  activation of the
expression of TGF-ßRII (TGF-ß type II receptor), preferably where the tumor cells exhibit
the EMT. Recently,  HMGA2 expression has also been associated with EMT in bladder
(Ding et al.,  2014), gastric (Zha et al.,  2013), liver (Luo et al.,  2013), and prostate cancer
(Zhu et al., 2013).
As mentioned above, HMGA2 is known to play an important role in the early development
of an individual. Part of this thesis focused on the detection of  HMGA2 in the placenta.
Besides  studying  normal  gestations,  another  investigation  dealt  with  a  certain  type  of
pathological pregnancies. In relatively rare cases of pregnancy, i.e. a molar pregnancy, the
embryo  is  lacking. A molar  pregnancy is  a  relatively  uncommon occurrence,  in  North
America and Europe 0.5-1.95 incidents per 1,000 pregnancies have been reported,  in
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Japan  2.0  to  2.5  per  1,000  (Bracken,  1987;  Jeffers  et al.,  1993;  Palmer,  1994).
Hydatidiform moles are classified as partial or complete moles. The closely related diploid
hydropic abortion is not considered molar. Complete hydatidiform moles (CHM) consist of
only  the  trophoblast  and  are  usually  diploid,  but  contain  only  paternal  DNA.  Partial
hydatidiform moles (PHM) also contain the anlage of the embryo and are in most cases
triploid  with  chromosomes deriving  from both  parents.  In  10  to  20 % of  the  CHMs a
gestational trophoblastic neoplasm, i.e. a malignant tumor, develops (Berkowitz, Goldstein,
1996; van de Kaa  et al.,  1996; Sebire, Seckl, 2008; Berkowitz, Goldstein, 2009; Kaneki
et al., 2010). The risk is considerably lower (Bagshawe et al., 1990; Cheung et al., 2004;
Feltmate et al., 2006; Hancock et al., 2006), or possibly nonexistent (Jeffers et al., 1993;
van de Kaa  et al., 1996; Niemann  et al., 2007; Kaneki  et al.,  2010;  reviewed in Hoffner,
Surti,  2012) in  case  of  the  PHM.  Hydropic  abortions  bear  no  risk  of  a  malignant
degeneration (Chen et al., 2012). Even though gestational trophoblastic tumors (GTT) are
usually highly susceptible to chemotherapy, 12 % of the women with a high risk form of a
GTT  die  after  developing  this  type  of  cancer  (Bower  et al.,  1997).  In  addition,
choriocarcinoma bears an elevated risk for the recipient after transplantation of an organ
(Marsh et al., 1987; Penn, 1995). Therefore, molecular markers to distinguish between the
two forms of molar pregnancies and hydropic abortions are of great interest.
The  group  of  testicular  germ-cell  tumors  (TGCT)  in  post-pubertal  patients  consists  of
several  histologic  subtypes:  seminomas,  embryonal  carcinomas (EC),  yolk  sac  tumors
(YST), teratomas, and choriocarcinomas (CC). They are characterized by a high incidence
of  up to 54 % of mixed-form neoplasias (Sesterhenn, Davis  Jr, 2004).  The subtype of
tumor is of clinical relevance (Albers  et al., 2003; Eble  et al., 2004; Krege  et al., 2008).
Therefore,  a  clinical  determination  of  the  components  by  a  pathologist  is  routinely
undertaken. Even though a number of antibodies is available, this identification can pose a
challenge  (Berney et al., 2012).  HMGA2 expression in TGCTs has been reported before
(Franco et al., 2008). The authors reported moderate to high expression of HMGA2 in ECs
and YSTs using immunohistology, Western-Blot, and RT-PCR. The aim of the investigation
part of this dissertation was to distinctively ascertain the expression level and test for a
possible clinical application, using highly sensitive qRT-PCR and immunohistochemistry.
Virtually all studies mentioned above investigated only one of the two genes analyzed for
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this thesis. There are a few studies involving both THADA and HMGA2, although never in
direct connection. Voight et al. (2010), who confirmed the association between a THADA
variant and T2D, also reported a new risk loci near  HMGA2 in context with the disease.
Louwers et al. (2013) and Saxena, Welt (2013) analyzed THADA and HMGA2 variants in
association with PCOS. While the two studies differ in part which SNPs for  THADA and
HMGA2 were analyzed, Louwers et al. (2013) reported a significant association between
THADA variants and PCOS, while Saxena, Welt (2013) did not find such a correlation. For
HMGA2, both groups conclude that there is no association between HMGA2 gene variants
and PCOS.
THADA was discovered in benign thyroid tumors. One main aspect of this thesis was to
advance the knowledge about the role of this gene in this organ, especially in hyper- and
neoplasias.  Since  an  association  between  THADA and  HMGA2 became  apparent  in
dedifferentiated thyroid tissue, focus was also directed towards this issue in other human
tissues.  Further  studies  were  aimed at  certain  aspects  of  HMGA2 in  extra-embryonic
tissue,  namely fetal  placenta,  and dedifferentiated testicular tissue,  through expression
analysis by quantitative real-time PCR and immunohistochemistry.
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2. Materials and methods
Detailed information about  materials  and methods is given in the publications II  to IV.
Additional content is provided in this section.
2.1. Establishing of THADA-vectors
For  determination  of  the  localization  of  THADA,  THADA ORF was  cloned  into  green
fluorescent  protein  vectors  pEGFP-C1  and  -N1  (Takara  Bio  Europe/Clontech,  Saint-
Germain-en-Laye, France). Full-length  THADA-A3 PCR product was kindly provided by
Norbert  Drieschner (Center for  Human Genetics at  the University of  Bremen).  After  A-
tailing with GoTaq Flexi polymerase (Promega GmbH, Mannheim, Germany), the fragment
was  ligated into  pGEM-T Easy (Promega),  in  both  cases following  the  manufacturer's
instructions. Transformation into DH5α (Merck Chemicals, Darmstadt, Germany) was done
according to the protocol by Inoue et al. (1990), clones were selected after a blue/white-
screening on AIX (100 μg/ml Ampicillin, 0,5 mM IPTG, 50 μg/ml X-Gal) agar plates. After
over-night culture in LB (Luria-Bertani) medium, glycerol stocks were prepared by adding
aliquots of 1 ml bacterial culture to 1 ml 60% (v/v) glycerol in a sterile reaction tube which
were stored at -80°C. Plasmid-DNA was isolated with the Qiagen Plasmid Midi Kit and the
QIAprep Spin Miniprep Kit,  respectively  (Qiagen, Hilden, Germany).  Sequence analysis
was performed by  Eurofins MWG Operon (Ebersberg, Germany), for assessment of the
data, Vector NTI (Invitrogen, Karlsruhe, Germany) and Chromas Lite  (Technelysium Pty
Ltd,  South  Brisbane,  Australia)  were  used.  For  replacement  of  sections  containing
mutations, pre-prepared subfragments of THADA ORF were utilized. These plasmids were
generated in identical fashion as the full length clone (see above). In addition, Pfu DNA
Polymerase  (Promega)  was  used  to  obtain  PCR  fragments,  according  to  the
manufacturer's instructions. Restriction enzymes AatII, ApaI, BamHI, BclI, BglII, Bsp119I,
Bpu1102I,  BshTI,  BstXI,  Eco32I, EcoO109I, EcoRI, Esp3I, HhaI, HindIII,  Kpn2I,  NcoI,
NdeI,  NotI,  PaeI,  PstI,  RsaI,  SalI,  TaqI,  TasI,  and  XhoI, and  in  addition,  CIAP,  T4
polymerase, and T4 ligase (all Fermentas, St. Leon-Rot, Germany), were used according
to the manufacturer's instructions. When necessary, DNA purification was performed with
the QIAquick PCR Purification Kit  (Qiagen).  To separate different DNA fragments after
digestion,  gel  electrophoresis  was  applied.  For  this,  depending  on  the  size  of  the
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fragments,  the  appropriate amount  of  agarose  (Biozym  Scientific  GmbH,  Hessisch
Oldendorf, Germany) was added to TAE buffer, the solution was heated until melting of the
agarose. It was then poured into a sealed  tray, simultaneously adding ethidium bromide
(Invitrogen)  to  the  final  concentration  of  150 ng/ml. After  hardening,  it  was  put  into  a
gelelectrophoresis  apparatus  (Gibco,  Karlsruhe,  Germany),  voltage  was  applied  via  a
power  supply unit  (Gibco).  Afterward,  the gel  was evaluated with  a gelelectrophoresis
documentation system (Biostep, Jahnsdorf, Germany), and the desired band was cut out
by scalpel (HMD Healthcare, Hereford, Great Britain). Isolation of the DNA was performed
with the QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions.
For transformation of the Plasmid-DNA into DH5α and isolation after over-night culture see
above. After sequencing and analysis of the data, only clones without mutations were kept.
Except for the blue/white screening, the same materials and methods were also applied for
construction of the following clones: THADA-A3 in pEGFP-C1, THADA-A3 in pEGFP-N1,
THADA-A3-Fus3p in pEGFP-C1 and THADA-A3-Fus3p in pEGFP-N1,  THADA-A3-Fus3p
being an aberrant form as detected by Rippe et al. (2003) in thyroid adenomas.
2.2. Cell lines and tissue samples
In all cases, human tissue samples and cell lines derived from human tissue, respectively,
were used.
2.2.1. Cell lines
Following  cell  lines  were  available  at  the  Center  for  Human  Genetics  (ZHG)  at  the
University of Bremen and were kindly provided by PD Dr. Gazanfer Belge: see table 1.
Table 1: Cell lines used for this thesis.
cell line tissue established by
S40.2/TSV40 thyroid adenoma PD Dr. G. Belge, ZHG
S121/TSV40 thyroid adenoma PD Dr. G. Belge, ZHG
S141.2/TSV40 thyroid adenoma PD Dr. G. Belge, ZHG
S211/TSV40 thyroid adenoma PD Dr. G. Belge, ZHG
S325/TSV40 thyroid adenoma PD Dr. G. Belge, ZHG
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cell line tissue established by
S533/TSV40 thyroid adenoma PD Dr. G. Belge, ZHG
FTC133 follicular thyroid carcinoma PD Dr. C. Schmutzler, Charité
FTC238 follicular thyroid carcinoma PD Dr. C. Schmutzler, Charité
HTH74 anaplastic thyroid carcinoma PD Dr. C. Schmutzler, Charité
S277 anaplastic thyroid carcinoma PD Dr. G. Belge, ZHG
Jurkat T-cell leukemia Dr. J. Minuwada, Fujisaki Cell Center
SupT1 T-cell lymphoma/leukemia Dr. M. Gramatzki, Uniklinik Erlangen
Myco 1T pleomorphic adenoma of the salivary glands PD Dr. G. Belge, ZHG
Li14/TSV40 lipoma PD Dr. G. Belge, ZHG
Fi primary cells skin fibroblast PD Dr. G. Belge, ZHG
tissue: tissue (tumor type) cell line deriving from.
2.2.2.  Snap-frozen lung samples
Lung cancer samples and the corresponding normal tissue specimens were collected at
the Clinical and Experimental Pathology of the Research Center Borstel, Germany.
2.2.3. Blood samples
Blood samples were taken at the Central Hospital Bremen-Mitte, Bremen, Germany and at
the Department of Internal Medicine, Division of Hematology and Oncology, University of
Rostock, Germany.
2.2.4.  Prostate samples 
Prostate  samples  were  collected  at  the  National  Institute  of  Public  Health  and
Environmental  Protection,  Department  of  Chronic  Disease  and  Environmental
Epidemiology, Bilthoven, the Netherlands.
2.2.5.  Snap-frozen normal tissues
Normal tissue samples (thyroid, salivary gland, lung, heart, myo- and endometrium, blood,
and adipose tissue) used in the  THADA expression study (section 3.2.) were collected
under the  supervision of the Center  for Human Genetics of  the University of  Bremen,
Germany.
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2.2.6. FFPE thyroid samples
Formalin-fixed paraffin-embedded (FFPE)  thyroid  tissue samples  were  collected at  the
Department of Pathology, Clinical Center Bremen-Mitte, Bremen, Germany.
2.2.7. FFPE placenta samples
FFPE placenta tissue samples and hydatidiform moles were collected at the Institute for
Pathology,  Elbe  Clinic  Stade-Buxtehude,  Germany,  and  the  Department  of  Pathology,
Clinical Center Bremen-Mitte, Bremen, Germany, respectively.
2.2.8.  Testis samples
Testis FFPE tissue samples were collected at the Department of  Pathology, Albertinen
Hospital, Hamburg, Germany, the Department of Pathology, Clinical Center Bremen-Mitte,
Bremen, Germany, and the Institute for Pathology, Elbe Clinic Stade-Buxtehude, Germany.
Additional FFPE samples were collected under the supervision of the Leibniz Institute for
Prevention  Research  and  Epidemiology,  Bremen,  Germany.  Snap-frozen  normal  testis
samples were collected by the  Department of Pathology, Clinical Center Bremen-Mitte,
Bremen, Germany.
2.3. RNA isolation and cDNA synthesis
For snap-frozen normal tissues and adipose tissue samples, RNA was isolated using the
RNeasy Mini Kit and RNeasy Lipid Tissue Mini Kit, respectively (Qiagen). For cell lines
TRIzol  reagent  (Invitrogen)  was  employed.  RNA  isolation  from  FFPE  blocks  was
performed utilizing a microtome. Depending on the size of the embedded tissue, six to
eight  cuts  of  5 µm  thickness  were  used,  for  snap-frozen  specimens  a  TissueLyser
(Qiagen)  was applied.  For separate investigations, different  isolation kits  were utilized.
Roche High Pure RNA Paraffin  Kit  (Roche,  Mannheim,  Germany)  was chosen for  the
THADA expression analysis in all but the placenta samples, RNeasy FFPE Kit (Qiagen)
was  used  in  the  NIS investigation.  In  the  remaining  tests, total  RNA isolations  were
performed using the innuPREP Micro RNA Kit  (Analytik Jena AG, Jena, Germany). All
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isolations were performed according to the manufacturer's instructions with the following
modifications for the innuPREP Micro RNA Kit:  Lysis of the paraffin sections preceding
RNA  isolation  was  conducted  using  TLS-Lysis  solution  and  Proteinase K  from  the
innuPREP DNA Micro Kit  (Analytik Jena) without  prior  deparaffinization. Sections were
incubated for 1 h at 60°C and 15 min at 80°C. Determination of RNA concentration was
performed by photometer (Eppendorf,  Hamburg,  Germany).  For  blood,  cell  lines,  lung,
prostate, and part of the placenta samples, RNA isolation was performed by Inga Flor
(placenta), Anke Meyer (cell lines, prostate), and Britta Meyer (blood, lung), respectively. In
these cases the isolated RNA was kindly provided.
RNAs were reverse-transcribed into cDNA by M-MLV Reverse Transcriptase (Invitrogen),
according to the manufacturer's instructions. In all cases, each sample contained 250 ng
RNA, 200 U enzyme and 150 ng random hexamer primer (Invitrogen).
2.4. qRT-PCR
Real-time PCR was performed using the Applied Biosystems 7300 sequence detection
system according to the TaqMan Gene Expression Assay Protocol (Applied Biosystems,
Darmstadt, Germany) in 96-well microtiter plates with a total volume of 20 µl. In case of
TaqMan  gene  expression  assays  for  THADA (assay  number  Hs00152982,  Applied
Biosystems,  Foster  City,  USA),  NIS (assay  number  Hs00166567_m1,  Applied
Biosystems),  and  HMGA2 (assay  number  Hs00171569,  Applied  Biosystems),  each
reaction consisted of 2 μl of cDNA reverse transcribed from 25 ng of total RNA, 10 μl of
TaqMan Universal PCR Master Mix (Applied Biosystems), 1 μl of TaqMan assay and 7 μl
of ddH2O. For the 18S rRNA assay, using 18S forward and 18S rev_1 primers (Antonov
et al., 2005), each reaction consisted of 2 μl of cDNA (1:10 diluted in ddH2O, with regard to
the higher expression of 18S rRNA in comparison to the genes above) reverse transcribed
from 25 ng of total RNA, 10 μl of TaqMan Universal PCR Master Mix, 600 nM of forward
and reverse primers, 200 nM of 18S probe (Antonov et al., 2005) and 5.4 μl of ddH2O. For
the HPRT assay, using HPRT FP and HPRT RP primers, and HPRT probe (Specht et al.,
2001), except for the dilution of the cDNA, the same conditions applied.  Thermal cycling
specifications were 2 min at 50°C followed by 10 min at 95°C, 50 cycles at 95°C for 15 s,
and 60°C for 1 min. A non-template control of amplification and two negative controls of
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previous cDNA synthesis (one without RNA and one missing reverse transcriptase) were
included  in  each  plate  for  the  NIS and  all  THADA investigations  except  for  placenta
samples.  For  HMGA2,  HPRT,  and  THADA in  the  placenta  studies  (normal  and  molar
pregnancies), and for  HMGA2 and HPRT in the testis study, for each sample a negative
control of previous cDNA synthesis (missing reverse transcriptase) and for each plate a
non-template  control  of  amplification  and  a  non-template  control  of  previous  cDNA
synthesis  were  included  in  each  run.  Software  Sequence  Detection  Software  1.2.3
(Applied Biosystems) was programmed with the reaction conditions. All testing reactions
were performed in triplicate. Gathered qRT-PCR data was analyzed using the comparative
CT-method (ΔΔCT-method) (Livak, Schmittgen, 2001).
2.5. Fluorescence in situ hybridization
Fluorescence in situ hybridization used for determinations of ploidy level of hydatidiform
moles was performed by Norbert Drieschner with technical assistance by Lisa Imbil and
Tais  Sommerfeld.  For  detection  of  polyploidy,  interphase-FISH  with  a  probe  mixture
containing a 1q12-specific probe (PUC1.77) and a centromere 6-specific probe (D6Z1;
pEDZ6)  was  performed  on  formalin-fixed,  paraffin-embedded  (FFPE)  tissue  sections.
Labeling of probes was done by nick translation (Abbott Molecular, Wiesbaden, Germany)
either with SpectrumOrange-dUTP (PUC1.77) or SpectrumGreen-dUTP (pEDZ6) (Abbott).
FISH  was  carried  out  as  described  previously  (Klemke  et al.,  2012)  with  a  few
modifications. Digestion of 4 µm tissue sections was performed with a pepsin ready-to-use
solution  (DCS,  Hamburg,  Germany)  at  37°C  within  a  range  of  30  and  45 min.  The
digestion time was optimized for each tissue section.  200 non-overlapping nuclei  from
different (at least four) areas of the tissue were finally scored, using a  Zeiss Axioskop 2
Plus (Carl  Zeiss Microscopy GmbH,  Göttingen,  Germany) microscope.  Nuclei  with  two
signals for each probe were scored as diploid, nuclei with three signals for each probe as
triploid, and those with four signals for both probes as tetraploid.
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2.6. p57KIP2 immunohistochemical analysis
p57KIP2-specific immunostaining  was  performed  by  Käte  Burchardt  on  representative
sections  from formalin-fixed,  paraffin-embedded  tissue  sections  of  all  samples  initially
diagnosed as hydatidiform moles, using a mouse antibody against the recombinant human
p57KIP2 protein (Zytomed Systems GmbH, Berlin, Germany). For the immunohistochemistry
the  SuperVision  2 HRP kit  was used (DCS, Hamburg,  Germany).  4 µm sections from
FFPE  blocks  were  incubated  on  slides  overnight  at  56°C.  The  tissue  sections  were
deparaffinized  in  xylene  and  alcohol,  then  blocked  with  3 %  H2O2 solution.  After
rehydration, the samples were incubated for 45 min in a steamer, using 0.01 M citrate
buffer, pH 6. This took place initially at room temperature heating up for about 20 min until
boiling for the rest of the duration, then cooled down for 20 min and rinsed with distilled
water.  Next,  the  slides  were  incubated  consecutively  in  antibody  solution  (1:3000  in
antibody diluent (Zytomed Systems)) for 30 min, in enhancer solution for 20 min, in HRP-
polymer solution for 20 min, in DAB 2 solution for 5 min, and in hematoxylin (1:2 in distilled
water)  for  5 min.  Between each of  these steps a  rinsing with  wash buffer  took place.
Finally, the samples were treated with alcohol and xylene and afterward sealed with Pertex
(Medite GmbH, Burgdorf, Germany).
Interpretation of p57KIP2 staining was performed by a pathologist, using a Zeiss Axioskop
microscope,  samples  were  considered  p57KIP2-positive  only  when  a  distinct  nuclear
immunostaining of villous stromal cells and cytotrophoblasts was observed. Samples with
faint nuclear staining were considered negative. Staining of intermediate trophoblasts and
maternal decidua served as the positive internal control.
2.7. Statistical analysis
Statistical calculations were done using R (The R Foundation for Statistical Computing,
Vienna, Austria) and SAS (SAS Institute Inc., Cary, North Carolina, USA).
The following analyses were utilized: The two-sided Wilcoxon rank sum test (equivalent to
the Mann-Whitney U test) and the Welch t test were used to compare average values from
two independent groups, respectively; relationships between two amounts were quantified
by linear regression, by a nonparametric spline model, or by Spearman’s rank correlation
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coefficient. Statistical models with nested sets of explaining quantities were compared by
the likelihood ratio test. Sensitivity, specificity and decision limits were calculated from non-
parametric density estimations. A p-value of less than 0.05 was considered significant, a
p-value of less than 0.001 was deemed highly significant. Analyses were performed with
Dr. Werner Wosniok (Institute of Statistics, University of Bremen).
Regarding the analyses of  THADA and  HMGA2 expression in section 3.3 (unpublished
results),  tests  for  normal  distribution  were  performed  according  to  Anderson-Darling,
Cramer-von  Mises,  Kolmogorov-Smirnov,  and  Shapiro-Wilk.  If  normally  distributed,
differences in expression were examined by a one-way ANOVA or Welch's ANOVA (in
case  variances  turned  out  to  be  unequal  as  suggested  by  the  Bartlett’s  test).  If  not
following a normal distribution, the Wilcoxon rank sum test or the Kruskal-Wallis test (in
case the  grouping variable  contained more  than two  categories)  were  conducted.  For
matched specimens, the Wilcoxon signed rank test was employed. Linear relations were
quantified  by  the  Pearson  correlation  coefficient.  Reliability  of  the  coefficient  of
determination (the squared Pearson correlation)  was checked by the F-test.  Statistical
consulting was kindly provided by Dr. Christian Astrosini.
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3. Results
3.1. Characterization of thyroid adenoma associated (THADA) gene 
and protein
Publication I: THADA - a protein with an important role in the thyroid 
(Kloth et al., 2012)
Investigations  by  Volkhard  Rippe  and  Norbert  Drieschner  at  the  Center  for  Human
Genetics at the University of Bremen revealed the frequent aberration of one at that point
in time unknown gene in thyroid adenomas. This gene was later named thyroid adenoma
associated (THADA)  (Rippe  et al.,  2003).  After  elucidation  of  its genomic  structure  by
in silico analysis, the aim of this study was to determine the cellular localization of the
protein.
THADA is located on chromosome 2, in band 2p21 and spans about  365  kbp.  In silico
analysis of expressed sequence tags (EST) revealed a number of relatively short exons in
the 5'-region of  the gene,  bringing the total  amount  to  38.  In  this  full-length form,  the
THADA ORF encodes for 1954 aa (THADA-A1), a splice variant without exons 27 and 28
contains 1880 aa (THADA-A2), a second one, missing exons 16 and 17, encompasses
1833 aa (THADA-A3).
To determine the localization of THADA in the cell, a plasmid containing the full-length ORF
of THADA-A3 was cloned. Splice variant THADA-A3 was used for the experiments, since
this form showed the highest expression as determined by RT-PCR on cDNA from cell
cultures. Several  cell  lines were tested as template.  As a result,  MCF-7 turned out  to
contain  a single nucleotide polymorphism  (A4946G).  This was not  the case for  S40.2,
which was consequently used as the template in the PCR. This amplicon was cloned into
pGEM-T Easy. In addition to this plasmid, a second one containing  THADA-A3-Fus3p, a
truncated form found in thyroid adenomas, also served as basis for the expression vectors.
In  separate  experiments,  pEGFP-C1-  and  pEGFP-N1-vectors  each  containing  the  full-
length (without exons 16 and 17) and the truncated ORF of THADA were transfected into
human lipoma cells. All variants containing part of or the full-length THADA ORF showed
the same pattern, i.e. a strong signal in the cytoplasm but none in the nucleus. For the
negative  controls  without  THADA,  the  protein  was evenly distributed in  the  cells.  This
investigation revealed that THADA is not a core protein and that the truncation of THADA
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does not cause a change in the location of its protein.
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21
?????????????????????????
????????????????????
??????????????????????????? ???????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
????????????? ??? ??????????? ??????????? ??????? ???? ??????? ???????? ??????? ?????
????????????????????????????????????????????????????????????????????????????
???????????????????????????????? ??????????????? ???????????????????????????
????? ????? ?????? ??? ??? ???? ??????? ????? ????????? ??????????? ????????????
????????????????????????????????????????????????? ????? ?????????????? ????
???????????????????????? ?????? ??????????????????? ???????????????? ???????????
??? ????????? ??????????????????????????????????????? ???? ??????????????????? ????
????????????? ????? ???????????????????? ???????????????????????????????????
????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
??????????????? ??????????????? ????? ????? ?????????? ?????? ????? ??? ??? ????
????????????????????????????????????????????????????
???????????????????????????????????????
?????? ???? ??????????????????????????? ?????? ??????? ???????? ?????????
???????????????????????????????????????????????????????????????????????????????
??? ??????????????? ????? ????????? ??? ???? ?????????? ???? ???? ???? ????????
?????????? ?????????????????? ???????? ??? ??????? ??????? ?? ????????????? ??? ????
????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????
????????????????????????????????????? ??????????????????????????????????????????????
???????? ???? ????? ?????? ??? ??? ????????? ???????? ???? ???????? ????????? ??? ????
???????????????????????????????????????
??????????
????????????????????????????????????????????
????????????????????????????????????????????
?????????????????????????????????????????????
??????????????????????
??????????????????????????????????????????????????????????????????????
?????? ???????????????? ????????? ???????????? ?????? ?????????? ????? ???? ?????
????????????????????????????????????????????? ????????????????????????????????
???? ?????? ?????? ???????? ??????????? ?????????????? ????????????????????????
????????????????????????????????????????????????????????????????????????????????
?????????? ????? ????? ??? ???????? ???????? ??? ????? ??? ?????? ??????? ?????
???????????? ???????????? ?? ??????? ?????????? ??????? ???? ?????????? ????????
????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????
????????? ??? ?? ??????????????????????????????????? ??? ???? ???????????? ????
?????????????????????????????
?????????????????????????????????????
??? ??? ?????????????? ???????? ?????? ?????????? ???????? ???????? ???? ?????????
?????????????????????????????????????????????????????????????????????????????
????????? ??????? ?????? ??????? ????? ???? ????????????? ??????? ???? ????????
???????????????????????????? ???????????????????????????????????
?????????????????????? ???????????????????????????????????????
??? ???????? ???????? ???????? ???? ?????????????? ???????????? ??????????? ????????
??????? ???? ???? ?????????????????? ??? ???????? ????????? ?????? ??????? ?????????
???????????? ??? ???????? ???? ??? ?????????? ??????? ????? ?????????? ?????????
???????????? ????? ?????? ??????????? ?????????? ???? ?????? ??? ???????????
??????????? ???????? ????????? ????????????????? ?????????????????? ????????????
?????? ????????? ???? ????? ??????? ?????????????? ?????? ??????? ??? ????????????
????????? ???? ??????????? ?????????? ?????? ??? ??? ???????????????????? ????????
????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????
??????????
?????? ???? ?????????? ??? ???? ??????? ????? ????????? ??? ???????? ??????????????? ???
???????? ????????? ???? ???????????? ?????? ????? ????? ??????? ???????????
?????????????????????????????????????????
???
???
???
???
??? ?? ??? ???? ??? ?? ?? ??? ?????????
??????? ??? ?????????? ??? ???????? ?????? ????? ?????? ????????????
???????????????????????????? ????
??????? ??? ????????????? ???
?????? ??? ???? ?????????? ????
???? ???? ???????? ??? ????????????
???????????????????????????????
?????????? ????? ????????
????????????????????????
??????????????????? ???? ??????????????????????? ???????????????????????????
?????????????????????????????????????????????????????????????????
Results
3.2. Quantitative analysis of THADA expression in thyroid lesions and 
normal tissues
Publication II: Decrease in thyroid adenoma associated (THADA) expression is 
   a marker of dedifferentiation of thyroid tissue (Kloth et al., 2011)
2p21 aberrations are one of the main chromosomal changes in thyroid adenomas. Rippe
et al. (2003) showed that these aberrations cause the truncation of THADA. Therefore, an
important  role  of  the gene in the thyroid seemed conceivable.  To test  this hypothesis,
THADA expression was measured in this organ and the values gathered were compared
to those of other normal tissues, using qRT-PCR. All thyroid samples showed a higher
expression than any of the other specimens. Overall,  the level  was significantly above
those of salivary gland, lung, heart, myo- and endometrium, blood, and adipose tissue.
In addition to the normal tissue samples THADA expression was also measured in thyroid
hyper-  and  neoplasias.  Eight  normal  tissue  samples,  18  goiters,  35  benign  tumors
(including  three  specimens  with  a  2p21  translocation),  and  32  malignant  tumors  (19
papillary carcinomas, five follicular carcinomas, four medullary carcinomas, four anaplastic
carcinomas) were tested. Samples with a 2p21 aberration showed only slight deviations
from the healthy tissue samples. Opposite to the differentiated thyroid adenomas, for the
highly  dedifferentiated  anaplastic  carcinomas,  the  level  of  expression  was  significantly
lower, indicating an involvement of THADA in the differentiation in thyroid cells.
Belge  et al. (2008)  found  HMGA2 to  be  a  marker  of  differentiation  in  thyroid  tissue,
applying qRT-PCR on part of the same samples used in this investigation. Comparing the
expression values of both genes revealed a significant correlation of THADA and HMGA2.
An increase in  HMGA2 is associated with a decrease in  THADA expression. Decreased
THADA expression as a marker for dedifferentiated thyroid tissue was further verified by a
significant  correlation  between  THADA and  NIS (sodium-iodide  symporter),  a  well
described marker of differentiation in the thyroid.
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Abstract
Background: Thyroid adenoma associated (THADA) has been identified as the target gene affected by chromosome
2p21 translocations in thyroid adenomas, but the role of THADA in the thyroid is still elusive. The aim of this study
was to quantify THADA gene expression in normal tissues and in thyroid hyper- and neoplasias, using real-time
PCR.
Methods: For the analysis THADA and 18S rRNA gene expression assays were performed on 34 normal tissue
samples, including thyroid, salivary gland, heart, endometrium, myometrium, lung, blood, and adipose tissue as
well as on 85 thyroid hyper- and neoplasias, including three adenomas with a 2p21 translocation. In addition, NIS
(sodium-iodide symporter) gene expression was measured on 34 of the pathological thyroid samples.
Results: Results illustrated that THADA expression in normal thyroid tissue was significantly higher (p < 0.0001,
exact Wilcoxon test) than in the other tissues. Significant differences were also found between non-malignant
pathological thyroid samples (goiters and adenomas) and malignant tumors (p < 0.001, Wilcoxon test, t
approximation), anaplastic carcinomas (ATCs) and all other samples and also between ATCs and all other malignant
tumors (p < 0.05, Wilcoxon test, t approximation). Furthermore, in thyroid tumors THADA mRNA expression was
found to be inversely correlated with HMGA2 mRNA. HMGA2 expression was recently identified as a marker
revealing malignant transformation of thyroid follicular tumors. A correlation between THADA and NIS has also
been found in thyroid normal tissue and malignant tumors.
Conclusions: The results suggest THADA being a marker of dedifferentiation of thyroid tissue.
Background
Benign thyroid tumors and hyperplasias of follicular
epithelial origin belong to the cytogenetically best ana-
lyzed human epithelial tumors.
Cytogenetic aberrations have been detected in
approximately 20% of these lesions [1]. Translocations
of chromosomal band 2p21 are the second most fre-
quent structural chromosomal rearrangement, repre-
senting a particular cytogenetic subgroup [2]. The target
gene has been identified and referred to as thyroid ade-
noma associated (THADA) [3].
The full length cDNA of THADA consists of 6,134 bp
distributed over 38 exons [GenBank: NM_022065].
There are two splice-variants, one lacking exons 27 and
28 [3], and the other without exons 16 and 17. The
THADA protein has three isoforms corresponding to
the three different transcript variants with 1953 [Gen-
Bank: NP_071348], 1879, and 1832 amino acids, respec-
tively. In adenomas with 2p21 translocations Rippe et al.
found different types of fusion variants of THADA [3].
In each case, THADA was truncated after exon 28 and
ectopic sequences fused to it were not correlated to any
known gene. Thus, it has been speculated that the trun-
cation rather than the fusion to ectopic coding
sequences is the critical event for the development of
the tumor [3].
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Studies by Drieschner et al. [4] revealed that the
mRNA, the protein size, and the genomic organization
is conserved among Homo sapiens, Canis familiaris,
Chlorocebus aethiops, Gallus gallus, and Mus musculus.
THADA proteins from the analyzed organisms showed
significant assignments to the superfamily ARM repeat
(SSF48371; Hidden Markov Models Superfamily data-
base), indicating the presence of a protein-protein-inter-
action-domain of that type.
The exact function of THADA still remains unclear.
Hypothetically, it belongs to the death receptor-interact-
ing proteins and is assumed to bind to death receptor
DR5 (Puduvalli VK and Ridgway L, GenBank accession
reference note), involving it in the TRAIL-induced apop-
tosis. The truncated THADA derived from the rear-
ranged allele might compete with the gene product of
the normal allele thereby disturbing normal apoptosis of
follicular cells, and subsequently altering the steady state
between proliferation and cellular death leading to ade-
nomatous growth in benign thyroid tumors with 2p21
translocations [3]. Nevertheless, there is a need for
further studies elucidating the role of THADA in nor-
mal thyroid development and in tumorigenesis.
Recently, a THADA variant has also been linked to
type 2 diabetes (T2D) [5], but this association has not
been confirmed by the majority of further studies [6-20].
During a meta-analysis of three genome-wide associa-
tion studies with individuals of European descent Zeg-
gini et al. found evidence for an association of a SNP
(rs7578597) in exon 24 of THADA and the susceptibility
for T2D [5]. Further indication for a correlation between
THADA and T2D was presented in several other publi-
cations [11,14,16,17,19], one reported an altered expres-
sion of THADA in pancreatic islets, using data from the
Diabetes Genome Anatomy Project (DGAP) database
[11]. In other investigations no correlation was detected
[6-8,10,12,13,15,18,20], except for one publication [9],
which reported an association between THADA SNP
rs7578597 and a 2-h insulin level during an oral glucose
tolerance test but no significant association between the
THADA SNP and T2D risk, rendering the association
disputable.
The aim of this study was to analyze THADA expres-
sion in thyroid tissue in comparison to other tissues and
to thyroid hyper- and neoplasias to elucidate the possi-
ble correlation of THADA mRNA with thyroid differen-
tiation and neoplastic growth.
Methods
Tissue specimen and RNA isolation
RNA from snap-frozen tissues was isolated using the
RNeasy Mini Kit and RNeasy Lipid Tissue Mini Kit for
the adipose tissue samples, respectively (QIAGEN, Hil-
den, Germany).
For the formalin-fixed paraffin-embedded (FFPE) tis-
sues of thyroid tumors, histopathologic diagnoses were
performed according to the World Health Organization
Classification of Tumours [21] (table 1). As to RNA iso-
lation, FFPE blocks were cut into six sections of 5 μm
for each sample using a microtome. Total RNA isola-
tions were performed using the Roche High Pure RNA
Paraffin Kit (Roche, Mannheim, Germany) for the
THADA expression investigation and the RNeasy FFPE
Kit (QIAGEN, Hilden, Germany) for the NIS expression
analysis. Three samples were cytogenetically character-
ized by 2p21 translocations. In all three cases, two of
which published previously [22,23], the breakpoints
were narrowed down to the THADA locus. One of the
anaplastic thyroid samples served as the source of a
newly established cell line. Cytogenetical analysis
revealed a highly complex karyotype with a range of 80
to 117 chromosomes (100.8 on average). Several marker
chromosomes, telomeric associations, and double min-
utes were detected.
cDNA-synthesis and real-time PCR expression analysis
RNAs were reverse-transcribed into cDNA by M-MLV
Reverse Transcriptase (Invitrogen, Karlsruhe, Germany).
Real-time PCR was performed using the Applied Biosys-
tems 7300 sequence detection system according to Taq-
Man Gene Expression Assay Protocol (Applied
Biosystems, Darmstadt, Germany) in 96-well microtiter
plates with a total volume of 20 μl. In case of TaqMan
gene expression assay of THADA (assay number
Hs00152982, Applied Biosystems, Foster City, USA), tar-
geting exons 31-32, and of NIS (assay number
Hs00166567_m1), each reaction consisted of 2 μl of
cDNA reverse transcribed from 25 ng of total RNA, 10
μl of TaqMan Universal PCR Master Mix (Applied Bio-
systems), 1 μl of TaqMan assay and 7 μl of ddH2O. For
the 18S rRNA assay, using 18S forward and 18S rev_1
primers [24], each reaction consisted of 2 μl of cDNA
(1:10 diluted, with regard to higher expression of 18S
rRNA) reverse transcribed from 25 ng of total RNA, 10
μl of TaqMan Universal PCR Master Mix, 600 nM of
forward and reverse primers, 200 nM of 18S probe [24]
and 5.4 μl of ddH2O.
Thermal cycling conditions were 2 min at 50°C fol-
lowed by 10 min at 95°C, 50 cycles at 95°C for 15 s and
60°C for 1 min. A non-template control of amplification
and two previous negative controls of cDNA synthesis
(one without RNA and one missing Reverse Transcrip-
tase) were included in each plate. Software Sequence
Detection Software 1.2.3 (Applied Biosystems) was pro-
grammed with the reaction condition. All testing reac-
tions were performed in triplicate.
Serial dilutions were made using cDNA derived from
25, 5, 1, 0.2, and 0.04 ng of total RNA from FFPE tissue
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of one thyroid adenoma for THADA and 18S rRNA, and
from fresh frozen tissue of one normal thyroid sample
for NIS. In each dilution, THADA, NIS, and 18S rRNA
gene expression assays were performed using absolute
quantification. Afterwards, the standard curves for both
assays were plotted with the log ng of input cDNA for
each dilution on the x-axis, and the matched CT value
on the y-axis. Furthermore, in order to evaluate the dif-
ferences of amplification efficiencies, the difference of
two curve slopes was calculated. If the absolute differ-
ence of the slopes is less than 0.1, the amplification effi-
ciencies of two assays are considered to be equal and
the comparative CT method is valid (User Bulletin No.
2, ABI PRISM 7700 Sequence Detection System,
Applied Biosystems). 18S rRNA was used as endogenous
control as suggested previously [25-28]. The 18S rRNA
assay showed an amplification efficiency of 92.6% (slope
= -3.514, R2 = 0.995). The THADA assay had an amplifi-
cation efficiency of 92.0% (slope = -3.531) and an R2-
value of 0.96. For NIS, the amplification efficiency was
93.4% (slope = -3.4917), the coefficient of determination
amounted to 0.997). As recommended for FFPE samples
[24,29-31] the fragment sizes amplified by all three
assays were small, ranging between 60 and 78 bp, a vali-
dation of these values was performed via gelelectrophor-
esis of the PCR-products (data not shown). When
applying the comparative CT method, one histological
normal thyroid tissue was used as calibrator sample.
Afterwards, data were compared with results from con-
ventional histology.
For statistical analysis, the Wilcoxon signed rank test
was used to compare average values (two-sided, exact
Table 1 Histology of the malignant thyroid lesions.
case no. age (years) sex histology tumor diameter (cm) TNM classification and grading
1 57 f PTC 0.9 pT1
2 31 m PTC 2.5 pT2 pN0
3 30 f PTC 2.5 pT2 NX
4 85 m PTC 4.0 pT3a
5 31 m PTC 2.0 pT3 pN1
6 54 f PTC 0.6 pT1 pNX pMX
7 49 f PTC 1.2 pT2
8 38 f PTC 0.6 pT1
9 50 f PTC 2.2 pT2
10 21 f PTC 1.0 pT1 pNX pMX
11 38 m PTC 0.8 pT1; G1
12 34 f PTC 2.3 pT2 pN1 pMX
13 66 f PTC 2.0 pT3; G2
14 25 f PTC 2.3 pT2 pN0
15 42 m PTC 0.7 pT1 N0 MX
16 42 f PTC 1.4 pT2a; G2
17 72 f PTC 1.0 pT1
18 84 f PTC 6.0 pT3 pNX
19 27 m PTC 2.5 pT2
20 35 f FTC 2.1 pT2 pN0 MX
21 66 f FTC 2.0 pT1
22 67 m FTC 5.5 pT3 pNX pM1
23 61 m FTC 8.0 pT4
24 53 f FTC pT4 pN1
25 61 m MTC 3.5 pT2 pN0
26 61 m MTC 1.7 pT2
27 52 m MTC 3.3 pT2
28 55 f MTC 2.2 pT2
29 76 f ATC 1.7 pT4b
30 76 f ATC 3.8 pT4b
31 86 f ATC 9.0 pT4 pN1b pM1
32 65 f ATC 2.0 pT4 N0; G4
All listed samples were used for the THADA expression investigation, for the NIS expression analysis samples 2, 3, 7, 13 and 24-28 were omitted. (PTC: papillary
thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid carcinoma; ATC: anaplastic thyroid carcinoma)
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version for at most 40 cases involved, otherwise using
the t approximation); relationships were quantified by
linear regression and Spearman’s rank correlation coeffi-
cient. Sensitivity, specificity and decision limits were cal-
culated from non-parametric density estimations.
Therefore, sensitivity and specificity may differ from raw
empirical values and decision limits need not coincide
with measured values. A p-value of less than 0.05 was
considered significant.
Ethics Statement
The use of human thyroid samples for this study was
approved by the local medical ethics committee (Ethik-
kommission bei der Ärztekammer Bremen) and followed
the guidelines of the declaration of Helsinki. Only samples
that were initially taken for diagnostic purposes were sec-
ondarily used for the present study. During pathological
examination, a sample of the tissue was snap-frozen. The
procedure was approved by the local ethics committee.
Because the samples were deidentified and were consid-
ered as samples normally discarded, the committee felt
that there was no specific patient consent necessary.
As for the normal tissue samples, these were anon-
ymously collected for earlier studies, each following the
guidelines of the declaration of Helsinki.
Results
THADA expression in normal tissues
Thirty-four snap-frozen samples from eight different tis-
sues were tested for the level of THADA expression.
The mean level per tissue type ranged from 1 (blood)
to 6.14 (thyroid), and the lowest single value for a
thyroid sample (4.04) was above the highest one (3.39,
myometrium) from any of the other tissues (Figure 1).
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Figure 1 THADA expression in normal tissues (snap-frozen samples). Boxplots for the relative quantifications of THADA gene expression in
normal tissues; tissue type at x-axis. (*): p < 0.0001 compared to all other tissues jointly (exact Wilcoxon signed rank test). Boxes contain the
inner 50% of all values and a bar at the position of the median, whiskers extend to the extrema of values or to 1.5 * box height, whichever is
smaller. The plus sign shows the arithmetic mean. (n: number of samples).
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Accordingly, statistical analysis using Wilcoxon’s exact
signed rank showed significant differences between
normal thyroid tissues and the group of all other tis-
sues (p < 0.0001). Using the THADA expression to dis-
criminate between thyroid and non-thyroid tissue, a
sensitivity of 82.5%, a specificity of 97.4% and an effi-
ciency of 95.2% with a decision limit value of 4.23
were achieved.
THADA expression in thyroid tumors
Ninety-three formalin-fixed-paraffin-embedded thyroid
samples, including eight normal tissues (from four
patients), 18 goiters, 35 benign, and 32 malignant tumors
were measured. For single tumor samples the expression
ranged between 0.065 (anaplastic carcinoma) and 2.986
(follicular adenoma) in relation to normal tissue, i.e. a
ratio of 1 : 45.94. Samples with a 2p21 translocation
showed a level of expression of 1.123, 1.624, and 0.662
fold, respectively. The mean values for the different
tumor entities ranged from 0.423 (anaplastic carcinoma)
to 1.156 (adenoma) (Figure 2 and table 2).
Significant differences of THADA expression were
noted between benign and malignant thyroid lesions.
Wilcoxon’s signed rank test showed a highly significant
difference comparing the joint group of goiters and
benign tumors with malignant tumors (p = 0.0009).
Using the exact Wilcoxon test, no significant differ-
ences were detected comparing the level of THADA
expression between normal tissue and benign lesions (p
= 0.2802) and papillary carcinomas (p = 0.2170). In con-
trast, significant differences were found between ana-
plastic carcinomas (ATCs), the most dedifferentiated
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Figure 2 THADA expression in thyroid hyper- and neoplasias (FFPE samples). Boxplots for the relative quantifications of THADA gene
expression in thyroid normal tissue, goiter, benign and malignant tumors; normal tissue and hyper-/neoplasia type at x-axis. Boxes contain the
inner 50% of all values and a bar at the position of the median, whiskers extend to the extrema of values or to 1.5 * box height, whichever is
smaller, isolated symbols indicate values outside this range. The plus sign shows the arithmetic mean. (n: number of samples).
Kloth et al. BMC Clinical Pathology 2011, 11:13
http://www.biomedcentral.com/1472-6890/11/13
Page 5 of 9
type of thyroid tumors, and all other samples (p =
0.0107) and ATCs and all other malignant tumors (p =
0.0234). Comparing anaplastic carcinomas with each
single group, the difference in expression between ATCs
and goiters (p = 0.0049) and adenomas (p = 0.0058)
were marked as significant. As this finding was a result
of systematically comparing anaplastic carcinomas with
the other lesions, a Bonferroni correction for multiple
testing was used (corrected a = 0.0083). Without the
need of correcting for multiple testing also normal tis-
sue and papillary carcinoma would have been assessed
as significantly different from anaplastic carcinoma (p =
0.0485 and p = 0.0350, respectively). Overall, significant
results were mostly seen with the group of anaplastic
carcinomas, indicating a relative stable level of expres-
sion in comparatively differentiated tissues with a signif-
icant reduction only in dedifferentiated tissues.
Recently HMGA2 expression has been shown to indicate
thyroid malignancy and can thus be considered marking
the dedifferentiation of thyroid epithelium [32-34]. As to
the study by Belge et al. [32] and the present one 48 sam-
ples were identical in both studies (seven normal tissues,
one goiter, 15 adenomas and 25 carcinomas, including
three anaplastic carcinomas). For these, RNA was isolated
from adjacent cuts of the same FFPE block and, except for
the different qRT-PCR assays, all samples were treated
identical in both investigations. Thus, it was feasible to
check these samples for a possible correlation between
THADA and HMGA2. Using Spearman’s rank correlation,
there was a highly significant inverse correlation between
THADA and HMGA2 expression (correlation coefficient =
-0.452; p = 0.0015), further underlining a possible role of
THADA in thyroid differentiation.
NIS (sodium-iodide symporter), the transmembrane gly-
coprotein accountable for the uptake of iodine in thyroid
cells, was found to be a marker of thyroid differentiation
[35-38]. To validate our findings NIS expression was mea-
sured in 41 samples, including seven normal tissue sam-
ples, six nodular goiters, five adenomas, and 23
carcinomas (15 papillary, four follicular, and all four ana-
plastic thyroid carcinomas). Using Spearman’s rank corre-
lation, no significant correlation (p = 0.1288) was detected
comparing THADA and NIS expression from all samples.
By contrast, a significant correlation was found constrain-
ing the analysis to the follicular and papillary carcinoma
samples (p = 0.0497, r = 0.456, n = 19), an even stronger
correlation between the expression of THADA and NIS
was found in normal and all malignant samples (p =
0.0021, r = 0.540, n = 30), and in normal tissue and ana-
plastic carcinomas (p = 0.0128, r = 0.718, n = 11)
Transcription factors binding to THADA
Using the SABiosciene DECODE Transcription Factor
Search, no THADA-promotor binding sites for thyroid-
specific transcription factors paired box gene 8 (pax8),
thyroid transcription factor 1 (TTF1), also known as
NK2 homeobox 1 (NKX2-1), and thyroid transcription
factor (TTF-2), sometimes referred to as forkhead box
protein E1 (FOXE1), were found. Amongst others
cAMP response element-binding protein (CREB), acti-
vating transcription factor (ATF-2), c-Jun, hepatic leuke-
mia factor (Hlf), and germ cell nuclear factor (GCNF)
were marked as relevant, FOXC1, Nkx2-2, Nkx2-5, and
Nkx6-1 were displayed with low relevance (data not
shown). HHEX (hematopoietically expressed homeobox)
has been found to be expressed in the adult thyroid
gland and in differentiated thyroid cell lines and to be
correlated with thyroid differentiation [39-41], but is not
included in the SABiosciene DECODE Transcription
Factor Search. A manual search for this transcription
factor revealed no assured binding sites in the THADA
promoter.
Discussion
In this study, THADA turned out to be highly expressed
in the thyroid compared to other normal tissues. In a
group of eight different types of tissue thyroid samples
showed a significantly higher THADA mRNA expression
than salivary gland, lung, heart, myometrium, endome-
trium, blood, and adipose tissue, hinting at a possibly
important role of THADA in the thyroid.
The results in part contradict data available online.
NCBI ESTProfileViewer predicted a higher expression in
heart and lung tissue and a slightly lower in the thyroid.
For uterus and blood the data are in concordance with
Table 2 Detailed view of THADA expression in thyroid
hyper- and neoplasias
sample type n average standard deviation median
normal tissue 8 1 0.217 0.959
goiter 18 1.15 0.303 1.132
nodular goiter 7 1.266 0.175 1.305
Graves disease 1 1.103 - 1.103
adenomatous goiter 10 1.073 0.369 1.021
adenoma 35 1.156 0.496 1.029
autonomous adenoma 2 0.873 0.212 0.873
follicular adenoma 27 1.158 0.522 1.029
macrofollicular adenoma 1 1.904 - 1.904
microfollicular adenoma 4 1.225 0.268 1.199
oncocytic adenoma 1 0.637 - 0.637
carcinoma 32 0.842 0.381 0.842
papillary carcinoma 19 0.872 0.352 0.858
follicular carcinoma 5 0.991 0.353 1.031
medullary carcinoma 4 0.932 0.391 0.834
anaplastic carcinoma 4 0.423 0.383 0.334
The arithmetic mean (with the standard deviation) and median relative
quantification of THADA gene expression in thyroid normal tissue, hyper- and
neoplasias are listed. (n: number of samples)
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those obtained from the EST-based estimates. For sali-
vary gland and adipose tissue the TPM (transcripts per
million)-values are zero, this could be due to an overall
small EST pool (20155 ESTs for salivary gland, 13106
ESTs for adipose tissue), resulting in less than one gene
EST (all normal tissues average: 31073 ESTs per gene
EST). Comparison to Affymetrix GeneChip Human
Genome array-based results from The Genomics Insti-
tute of the Novartis Research Foundation (GNF) showed
similar discrepancies. There are three probes, one
(gnf1h10751_at) is diverging considerably from the
other two and was therefore omitted. Compared to our
data both remaining probes resulted in similarly average
Spearman’s rank correlation coefficients and no signifi-
cances (p ≥ 0.2). GNF results showed thyroid as the tis-
sue with the highest THADA expression but less distinct
from the other tissues. Overall, the more precise and
reliable qRT-PCR-method disclosed results that are
diverging from those available from online databases.
Furthermore, evidence that THADA expression is
associated to thyroid differentiation has been presented.
Analysis of 93 thyroid FFPE samples revealed significant
differences between benign and malignant thyroid
lesions, especially when comparing the group of anaplas-
tic carcinomas with other types of lesions. Despite one
outlier with an expression level almost identical to nor-
mal tissue, the values were significantly lower compared
to all other samples as well as to all other malignant
tumors. A comparison of the expression level of
THADA and NIS (sodium-iodide symporter) confirmed
these observations. Amongst others, a significant corre-
lation between THADA and this well established marker
of thyroid differentiation [35-38] has been detected in
normal tissue and anaplastic carcinomas. This suggests
that THADA expression decreases with dedifferentiation
of the thyroid epithelium. This hypothesis is further
supported by the significant inverse correlation between
the expression of THADA and HMGA2. Belge et al. [32]
showed that HMGA2 is significantly overexpressed in
malignant thyroid tumors compared to benign lesions.
As a rule, a high HMGA2 expression seems to be
accompanied by a low THADA expression. As yet the
underlying mechanism is unknown but it does not seem
to involve thyroid-specific transcription factors, since no
binding sites for pax8, TTF-1 and -2 were found. How-
ever, the SABiosciene DECODE Transcription Factor
Search revealed a binding site of the cAMP response
element-binding protein (CREB). CREB has been shown
to regulate diverse cellular responses, including differen-
tiation [42], targeted expression of dominant-negative
mutants of CREB in transgenic mice has been associated
with thyroid hypoplasia [43]. cAMP indirectly plays a
crucial role in the differentiation of endocrine tissues
[43], including the thyroid [44,45]. Thus one might
speculate about an involvement in the decreased expres-
sion of THADA in dedifferentiated thyroid cells.
In thyroid adenomas THADA was frequently found to
be truncated [3]. Whereas the intact THADA may be
involved in maintaining the differentiation of thyroid
epithelium, the truncated allele might play a key role in
tumor development of the thyroid. While competing
with the full-length protein translated from the normal
allele of THADA the altered protein derived from the
truncated gene might lead to an impaired induction of
apoptosis, and subsequently give rise to an increased
cell proliferation leading to benign thyroid tumors with
2p21 translocations [3], without significant changes of
the expression level.
Conclusions
THADA expression, though not restricted to the follicu-
lar cells of the thyroid, is higher in the thyroid than in
other tissues tested (salivary gland, heart, endometrium,
myometrium, lung, blood, and adipose tissue). As to its
normal function, THADA expression has been found to
be decreased in anaplastic carcinomas and to be corre-
lated with the expression of NIS, a marker of thyroid
differentiation, and inversely correlated with that of
HMGA2, a marker of malignant transformation of the
thyroid and cancer stemness. It may thus have essential
functions in maintaining the differentiation of the folli-
cular epithelium.
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Results
3.3. Investigations into the suspected correlation of THADA and 
HMGA2 expression (unpublished results)
After uncovering the negative correlation between the expression of THADA and HMGA2
in dedifferentiated thyroid samples (see section 3.2), the following studies were carried out
to test if this association is also true for neoplasias of other tissues in humans. Tested were
several  groups  of  hematologic  diseases,  including  acute  and  chronic, myeloid  and
lymphocytic leukemia (AML, CML, ALL, CLL), carcinomas of the lung and the prostate,
several cell lines, and as non-neoplastic specimens fetal placenta samples. Overall, the
correlation could not be confirmed in the above tissues, restricting it at the present state of
knowledge to the thyroid (table 2). Although in case of prostate carcinomas with a low
Gleason score and in thyroid cell lines results might hint at a tendency (see section 3.3.1.
and 3.3.3.,  respectively),  but  increasing  the  number  of  samples  is  necessary for  final
evaluation.  This  might  also  be  the  case  for  carcinomas  of  the  lung,  especially  for
squamous cell carcinomas, in which initial analysis yielded a highly significant correlation,
but further tests challenged these results. All expression data gathered in the studies can
be found in the appendix (section 10).
The relatively low to very low variation in expression level of  THADA in comparison to
HMGA2 resulted  in  no  statistically  significant  differences  between  clinical  subgroups
(defined by differences in type of tumor, histological grading, tumor stage, or patient's age)
in any of the investigations.
Overall,  in  combination  with  the  findings from the  study presented in  section  3.2,  the
results further underline the particular role of THADA in the thyroid.
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Table 2: Summary of the statistical analysis of THADA- and HMGA2-expression in human 
tissues and blood.
study number of samples R2 p
cell lines 9 0.0542 0.5466
carcinomas of the lung 18* 0.0421 0.4143
prostate carcinomas 14 0.0483 0.4503
hematologic diseases 55 0.0595 0.0728
fetal placenta 106 0.0310 0.0712
For each study, numbers always only include samples with data for both genes available. *: In each case,
expression  data  from tumor  samples  were  normalized  by  the  value  from corresponding  normal  tissue
specimens from the same patient (see also text, section 3.3.2).
Own contribution:
Study design with Jörn Bullerdiek
Execution  and  analysis  of  the  study  on  cell  lines,  carcinomas  of  the  lung,  prostate  
carcinomas,  and  hematologic  diseases  for  THADA expression except  for  RNA  
isolation for part of the samples
Execution and analysis of the study on fetal placenta samples for  THADA and  HMGA2 
expression except for RNA isolation for part of the samples
Statistics with Christian Astrosini
3.3.1.  Cell lines
In addition to the primary samples (sections 3.3.2. to 3.3.5.) nine cell lines were tested.
Among these, five derived from thyroid tumors (two adenomas, two follicular carcinomas,
and  one  anaplastic  carcinoma).  Also  tested  were  four  cell  lines  derived  from  other
neoplasias, in two cases from T-cell leukemias, one derived from a pleomorphic adenoma
of the salivary glands and one from a lipoma.
Relative qRT-PCR data of HMGA2 was kindly provided by Anke Meyer (Center for Human
Genetics, University of Bremen). Part of the  THADA expression data was published in
Drieschner  et al.  (2006).  Results  from  statistical  tests  clearly  indicated  no  correlation
between the expression of THADA and HMGA2 (R2 = 0.0542; p = 0.5466). A positive trend
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was suggested when testing the cell lines derived from thyroid tumors alone (R2 = 0.5422;
p = 0.1559),  whereas  the  strength  of  correlation  further  decreased  for  the  remaining
specimens in a joint group (R2 = 0.0195; p = 0.8605).
Six additional cell  lines were tested for  THADA expression. Four of these derived from
thyroid adenomas, one of an anaplastic thyroid carcinoma, one was a primary culture of
skin  fibroblasts.  Choosing the  cell  line  with  the  lowest  expression  as  the  calibrator,  a
maximum fold change of 14.95 times was observed. The Mann-Whitney-U test  revealed
no significant difference in expression between the cell lines deriving from thyroid tumors
and those from non-thyroid specimens.
3.3.2.  Carcinomas of the lung
Matched normal tissue and tumor samples from 18 patients with carcinomas of the lung
were  analyzed.  All  specimens  were  non-small-cell  lung  carcinomas,  50 %  were
adenocarcinomas, the other half squamous cell carcinomas. Five tumors were of grade 1,
six were of grade 2, and seven of grade 3. Except for one patient, in all cases stage of the
disease was also stated.
Absolute quantification qRT-PCR data of  HMGA2 was kindly provided by Britta  Meyer
(Center for Human Genetics, University of Bremen). The data for HMGA2 was published in
Meyer  et al.  (2007a).  Initial  analysis  with  all  36  samples  showed  a  highly  significant
correlation between the expression of THADA and HMGA2 (R2 = 0.3135; p = 0.0004). This
result  could  not  be  reproduced  for  the  group  of  adenocarcinomas  (R2 = 0.0969;
p = 0.2085),  but  for  the squamous cell  carcinomas,  the correlation  proved to  be  even
stronger (R2 = 0.6393;  p < 0.0001). Further tests showed significant or highly significant
correlations  in  the  subgroups  of  samples  from  patients  with  tumor  grade 1,  grade 2,
stage 1 and stage 2. Due to the limited number of samples available, substagings (“A” and
“B” suffixes) were neglected. Testing the tumor specimens alone, the results were very
similar. Only for the subgroups “grade 2” and “stage 1” the outcome differed, for these p
was above 0.05. Regarding the normal samples, only for samples from patients with a
squamous cell carcinoma a significant correlation could be detected.
To eliminate a bias potentially due to divergent baseline expression in the lungs of different
patients, a normalization of expression values was applied as follows: Each value from a
tumor sample was divided by the matched normal tissue's value, i.e. an expression value
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relative to the corresponding normal specimen was generated. For these 18 values, the
same  statistical  tests  as  above  were  utilized.  Comparing  the  THADA and  HMGA2
expression following this method, there was neither a significant difference observed for all
samples (R2 = 0.0421; p = 0.4143), nor one for any of the subgroups mentioned above.
Visual assessment of the corresponding scatterplot from the analysis with all 36 samples
(not normalized) with HMGA2 expression values on the x-axis and THADA values on the
y-axis showed an almost linear distribution of data points along the x-axis, with only four
outliers above this virtual line on the right, putting the results from the initial analyses in
doubt  (data  not  shown).  Additionally,  since  the  corresponding  normal  tissue  of  tumor
samples cannot have a grading, staging and cannot be regarded as adenocarcinomas or
squamous  cell  carcinomas,  and  therefore  not  separated  as  such,  the  latter  statistical
method (normalized values) was used for final evaluation.
Analysis  of  the  expression  data  of  THADA showed  a  range  of  1  to  5.17  times.  No
significant  difference  in  THADA expression  level  could  be  detected  between  the
subgroups, separating the samples by histological category, age of the patient, stage, or
grade. These results were in concordance independent of testing all samples, the tumor or
the  normal  specimens separately,  or  using  the  normalized values.  There  was also  no
significant difference in THADA expression between all normal and all tumor samples, nor
in any of the subgroups.
3.3.3. Prostate carcinomas
Fourteen prostate cancer samples were investigated. One specimen had a Gleason score
of 5, for three samples it was 6, for another three it was 7, four cases had a score of 8, and
for yet another three it was 9. In each case, the Gleason grading was also stated. Relative
quantification qRT-PCR data of  HMGA2 was kindly provided by Anke Meyer (Center for
Human Genetics, University of Bremen). No correlation between the expression of THADA
and HMGA2 could be detected (R2 = 0.0483; p = 0.4503). This was also true when testing
the samples separated by Gleason grading and by Gleason score, respectively. Although
in both cases the coefficient of determination was above 0.9 within the subgroups of lower
scores 6 and 7, a  p-value well above 0.05 indicated no significance, possibly due to the
low sample size. Only a single sample had a score of 5, hence no R2 could be determined.
The  same  results  were  obtained  within  the  subgroups  of  those  gradings  resulting  in
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Gleason  scores  below  eight.  For  the  specimens  with  a  higher  score  (8  and  9)  and
corresponding grading, R2 showed a progressive decline, p a further incline.
There was one additional sample available for assessment of THADA expression, a tumor
with a Gleason score of 6. Overall,  THADA expression ranged from 1 to 3.31 times. A
significant difference in expression could neither be detected when separating the samples
by Gleason grading nor by Gleason score.
3.3.4.  Hematologic diseases
Forty-eight samples of hematologic neoplasias (15 AMLs, five CMLs, seven ALLs, three
CLLs,  eight  other  myeloproliferative  neoplasms,  and  ten  malignant  lymphomas) were
investigated, accompanied by seven outside controls from patients with other diseases
(two other neoplasias, two cases of systemic lupus erythematosus, and three other non-
neoplastic diseases). Seventeen samples were taken before start of the therapy, 26 during
and eleven after the end of the therapy, and for one specimen there was no information
available about when the sample was taken. In all cases the patient's age, and in all but
two the blood cell concentration was stated.
Absolute quantification qRT-PCR data of  HMGA2 was kindly provided by Britta  Meyer
(Center  for  Human Genetics,  University of  Bremen).  Five  specimens were  part  of  the
investigation published in Meyer  et al.  (2007b).  Performing a linear regression analysis
including the THADA and HMGA2 expression values from all 55 samples, the coefficient of
determination amounted  to  0.0595  with  a  p-value  of  0.0728,  suggesting  that  the
expression levels  are not  correlated.  Checking individual  disease types alone,  R2 was
between  0.0223  (ALL)  and  0.2632  (malignant  lymphoma);  the  F-test  revealed  no
significant correlation in any of these subgroups.  Neither could there one be detected in
the  joint  group  of  hematologic  neoplasias  nor  in  the  outside  controls  taken  alone
(R2 = 0.0597 and 0.1856, respectively). When grouping the samples by phase of therapy, a
p-value of  0.0154 (R2 = 0.2210)  could  be  ascertained  for  the  specimens taken during
therapy if  no outliers  were excluded.  Nevertheless,  further analysis  showed that  these
numbers  depended  on  a  single  sample,  when  retesting  the  subgroup  without  this
specimen (25 samples remaining), the slope of the regression line was reversed and no
longer significant (R2 = 0.0685;  p = 0.2062). Both subgroups representing samples taken
before as well as after therapy showed no significant correlation, either.
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In  addition  to  the  samples  with  data  for  both  genes  a  further  eight  specimens  were
analyzed for the expression of THADA alone. Seven samples were from healthy subjects,
i.e. normal blood samples, one was from a patient with CML. This specimen was taken
during therapy. For the normal blood samples, age of each individual and cell  number
were not available. Overall, for  THADA the expression range for the specimen with the
lowest and the one with the highest value was 1 to 26.31 times. There was no statistically
significant difference in expression levels observed between individual disease types, the
joint  groups  of  hematologic  neoplasias  versus  joint  outside  controls  versus  normal
samples,  or  different  therapy phases.  Nor  could  a  significant  correlation  between  the
expression of THADA and the patient's age be detected. When comparing the expression
with the cell number, results indicated there was only a very weak correlation between
THADA expression and the amount of cells per liter blood (R2 = 0.1194; p = 0.0105).
3.3.5.  Fetal placenta
All  samples from section 3.4 (Kloth  et al., in preparation) were also tested for  THADA
expression as part of this study. These consisted of 90 fetal  placenta specimens from
calendar  gestational  ages  (CGA)  of  five  up  to  41  weeks.  Additionally,  eight  samples
without information about the GA were also investigated. These were accompanied by two
hydropic  abortions  (HA),  two  partial  hydatidiform  moles  (PHM)  and  four  complete
hydatidiform  moles  (CHM).  For  these,  in  five  cases  the  GA was  stated.  Of  the  106
samples, 102 were collected after an early termination of the pregnancy, of these, 70 were
spontaneous, 21 were  induced abortions (none with medical indication), and for eleven
there  was  no  information  about  the  type  of  abortion. Four  specimens  were  gathered
postnatally.
Neither  could  a correlation  between  the  expression  of  THADA and  HMGA2 in  fetal
placenta be detected for the non-molar pregnancy samples (R2 = 0.0303; p = 0.0864), nor
for the molar pregnancy and hydropic abortion specimens in a joint group (R2 = 0.2533;
p = 0.2036).  This is also true for all  samples combined as well  as within each distinct
abortion type subgroup. When comparing the expression values for only the samples from
the  first  trimester,  R2  (0.1215)  and  p (0.0019)  indicated  a  significant  yet  marginal
correlation. These numbers were almost identical when omitting the molar pregnancy and
hydropic abortion specimens (R2 = 0.1222; p = 0.0026). For the samples from the second
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and  third  trimester  combined,  no  significant  correlation  was  observed  (R2 = 0.1975;
p = 0.0647).
Considering all samples,  THADA expression showed a range of 1 to 13.05 times, which
was  also  the  case  for  the  non-hydropic  placenta  samples  considered  alone.  For  the
hydropic  abortions  and  hydatidiform  moles  the  difference  in  expression  between  the
sample with the lowest value to the one with the highest one was 1.65 times. The same
statistical tests as presented in section 3.4 (Kloth et al., in preparation) used to analyze the
expression of  HMGA2 were performed to evaluate the one of  THADA. In contrast to the
former,  THADA expression showed no significant differences between the groups in any
regard.
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3.4. Quantitative analysis of HMGA2 in fetal placenta
Publication III: Expression of HMGA2 in fetal placenta correlates with 
gestational age (Kloth et al., in preparation)
Following  the  elucidation  of  the  very  low correlation  between  the  expression  level  of
THADA and HMGA2 in fetal placenta samples of the first trimester, the focus was directed
towards the study of  HMGA2 in this tissue. While no relation between  THADA and the
CGA could  be  detected,  for  HMGA2 a  highly  significant  correlation  was  discovered.
Samples as described in section 3.3.5. were analyzed, those without information about the
CGA were not used for this study. For all specimens the coefficient of determination was
0.413, for those collected after an induced abortion or after birth it turned out to be 0.791,
and for the specimens gathered after a spontaneous abortion it was 0.186. In each case,
p was below 0.001. HMGA2 expression was high in the early gestation. Around the end of
the first trimester the level showed a decline up to a CGA of 28 weeks, after this, only a
baseline  expression  was  detectable.  Hence,  there  was  a  highly  significant  difference
between  samples  from  the  first  trimester  and  those  from  the  joint  second  and  third
trimester. For the most part, immunoreactivity was consistent with the qRT-PCR. Samples
with a low CGA showed intense signals, whereas those from specimens from late stages
of pregnancy were barely detectable. Throughout all samples, there was a clear pattern
for the localization of HMGA2. Relative to each specimen's level of staining, the strongest
signals were detectable in the nuclei of the stroma cells, slightly less intense staining was
visible in the cytoplasm of the trophoblast.
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Abstract
Background
High-mobility group AT-hook 2 (HMGA2) expression can be detected in many embryonic
and fetal tissues but becomes down-regulated in adult tissue. The placenta is essential for
the  development  of  the  embryo  and  the  fetus.  It  grows  rapidly  in  the  first  weeks  of
gestation.  There  are  several  research  papers  discussing genes  involved  in  the
development of the placenta. However, this is the first investigation measuring  HMGA2
expression throughout the whole duration of pregnancy.
Methods
Expression of  HMGA2 and  HPRT was measured on 90 fetal  placentas, encompassing
calendar gestational ages (CGA) of five to 41 weeks, using quantitative real time-PCR
(qRT-PCR). In eleven cases, an antibody specific for HMGA2 was used to determine the
localization of the protein and to verify the qRT-PCR data.
Results
The  expression  of  HMGA2 is  highly  significantly  correlated with  the  gestational  age
(p < 0.001). For the better part of the first trimester the level of HMGA2 is high, after that
the expression shows a decline down to a baseline level, where it remains until the birth.
HMGA2 protein was mainly detected in the nucleus of the stromal cells in the placental
villi.
Conclusions
In fetal placenta the expression of HMGA2 follows a certain pattern. In the first trimester,
from two to three weeks after the implantation of the conceptus until the blood supply is
established, the expression is high, indicating a critical role in the early development of this
organ.
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Background
The HMGA-(High-mobility  group  AT-hook-) group is  a  family  of  non-histone  chromatin
proteins, encoded by two genes,  HMGA1 and HMGA2. Due to alternative splicing, there
are four known proteins (HMGA1a, HMGA1b, HMGA1c, and HMGA2) [reviewed in 1,2].
HMGA2-proteins  are  architectural  transcription  factors  and  contain  three  DNA-binding
domains, called AT-hooks, and an acidic carboxy-terminal tail. As such, they do not have
an intrinsic transcription factor capacity, but rather enhance or silence transcription through
a change in chromatin structure and interaction with nuclear proteins [reviewed in 3,4].
They play a key role in the mammalian growth and development of tissues and, in some
cases, the differentiation of cells [5-9]. Especially in the case of HMGA2, the expression is
not detectable in most adult tissues with the exception of spermatocytes and spermatides
in testis  [10-14].  HMGA reactivation in adult tissue was first reported in HeLa cells [15].
Since then,  the overexpression of  HMGA1 and -2 was detected in numerous types of
cancer cells [reviewed in 1,2,16].
The placenta is the only normal human tissue which shows infiltrating behavior, albeit, as a
rule, in a tightly restricted manner. It serves as the connection between the mother and the
embryo or fetus, providing nutrients and oxygen for the developing child. Additionally, it
removes waste products from the fetus and forms a maternal-fetal barrier,  protecting the
fetus from microbes and cloaking it from the mother's immune system. About six days after
fertilization, the blastocyst begins the implantation into the maternal uterus and starts the
placentation. Five weeks after conception the basic structure of the placenta has formed.
To support the developing fetus, it continues to grow throughout gestation.
The expression of HMG-proteins in the placenta has been reported as early as 1987.
Corfman et al. [17] discovered the presence of HMGB and -N in human term placenta. The
detection of HMGA2 expression in the placenta dates back to 1996 [11]. To detect HMGA2
mRNA, RT-PCR was used on several fetal tissues of a gestational age between eight to
twelve weeks and on maternal and fetal placenta of 36 weeks. The experiments yielded
positive  results  for  the  embryo,  but  negative  findings  for  the  placenta.  In  another
investigation  [13]  RNA in  situ  hybridization  was  used  on  mouse  embryo  sections for
detection of  HMGA2 mRNA, including fetal placenta. Here - in comparison to nearly all
parts of the embryo - reduced expression of HMGA2 was found at a developmental stage
of 9.5 [13]. HMGA2 mRNA was also detected by RT-PCR, but not by northern blot analysis
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in  three  fetuses  of  19  to  22  weeks  estimated  gestational  age  by  Gattas  et al.  [18].
Genbacev et al. [19] identified the chorionic mesoderm as a niche for human trophoblastic
progenitor cells that support placental growth. HMGA2 was found to be one of the factors
associated with the self-renewal or differentiation of these cells.
The  aim  of  the  present  paper was  to  determine  if  there  is  a temporally  and  spatial
expression pattern of  HMGA2 in the fetal placenta. In case of a correlation between the
pattern and the invasive growth of the placenta, this would provide first insights into the
role of HMGA2 in the development of this organ.
Methods
Tissue specimens collection and RNA isolation
Formalin-fixed paraffin-embedded (FFPE) tissue samples were collected at the Institute for
Pathology,  Elbe  Clinic  Stade-Buxtehude,  Germany.  Pathological examinations  were
performed after haematoxylin and eosin staining of the samples. Depending on the size of
the embedded tissue, FFPE blocks were cut into six to eight  sections of 5 μm for each
sample  using  a  microtome.  Total  RNA isolations  were  performed using  the  innuPREP
Micro RNA Kit  (Analytik  Jena AG,  Jena,  Germany)  for  RNA isolation according to  the
manufacturer's instructions with the following modifications: Lysis of the paraffin sections
preceding RNA isolation was conducted using TLS-Lysis Solution and Proteinase K from
the innuPREP DNA Micro Kit (Analytik Jena AG) without prior deparaffinization. Sections
were incubated for 1 h at 60°C and 15 min at 80°C.
cDNA-synthesis and quantitative real-time RT-PCR
RNAs were reverse-transcribed into cDNA by M-MLV Reverse Transcriptase (Invitrogen,
Karlsruhe, Germany). Real-time PCR was performed using the Applied Biosystems 7300
sequence  detection  system  according  to  Taq-Man  Gene  Expression  Assay  Protocol
(Applied Biosystems, Darmstadt, Germany) in 96-well microtiter plates with a total volume
of 20 μl.  In the case of the TaqMan gene expression assay for  HMGA2 (assay number
Hs00171569, Applied Biosystems, Foster City, USA), each reaction consisted of 2 μl of
cDNA reverse transcribed from 25 ng of total RNA, 10 μl of TaqMan Universal PCR Master
Mix (Applied Biosystems), 1 μl of TaqMan assay and 7 μl of ddH2O. For the HPRT assay,
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using  HPRT FP and  HPRT RP  primers  [20],  each  reaction  consisted  of  2 μl  of  cDNA
reverse transcribed from 25 ng of total RNA, 10 μl of TaqMan Universal PCR Master Mix,
600 nM (1.2 μl) of forward and reverse primers, 200 nM (0.2 μl) of probe [20] and 5.4 μl of
ddH2O.  Thermal  cycling  conditions  were  2 min  at  50°C  followed  by  10 min  at  95°C,
50 cycles at 95°C for 15 s and 60°C for 1 min. For each sample, a negative control of a
previous  cDNA synthesis  (missing  reverse  transcriptase)  and  for  each  plate  a  non-
template control of amplification and a non-template control of previous cDNA synthesis
were included in each run. Sequence Detection Software 1.2.3 (Applied Biosystems) was
programmed with the reaction conditions. All testing reactions were performed in triplicate.
Considering the expression range of HMGA2, HPRT was used as endogenous control, as
it has previously been shown to be stably expressed in human fetal placenta [21-23]. As
recommended for FFPE samples [24] the fragment sizes amplified by both assays were
small, ranging between 65 and 80 bp. A validation of these values was performed via gel
electrophoresis of the PCR (data not shown). When applying the comparative CT method,
the sample with the lowest value was used as calibrator.
HMGA2 immunohistochemical analysis
Slides utilized for the  immunohistochemical  analysis  were produced using cuts directly
adjacent to those employed for the qRT-PCR investigation. Immunohistochemical staining
for  HMGA2 (rabbit  polyclonal  anti-HMGA2-P3,  Biocheck,  Inc.,  Forster  City,  USA)  was
performed using a detection kit  (DAKO ChemMate;  DAKO, Glostrup,  Denmark)  and a
semi-automated  stainer  (DAKO;  TechMate)  according  to  the  specifications  of  the
manufacturer. For antigen retrieval the slides were treated in a PT Link module (DAKO)
using  the  EnVision™  FLEX  Target  Retrieval  Solution,  low  pH  (DAKO).  The  antibody
dilution used was 1:500.
Statistical analysis
The  two-sided  Wilcoxon  rank  sum  test  was  used  to  compare  averages  from  two
independent  groups.  Relationships between two observed or  measured amounts  were
quantified by linear regression or by a nonparametric spline model, if the latter turned out
to  have a significantly better  fit.  Models were  compared by the likelihood ratio  test.  A
p-value of less than 0.05 was considered significant, a p-value below 0.001 was deemed
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highly significant.  Statistical  calculations were done using the R package, version 2.15
[25]. 
Ethics Statement
All samples investigated were initially taken for diagnostic purposes and secondarily used
for the present study. Samples were deidentified before their use in this study, in line with
the rules of the Helsinki declaration. The study was approved by the local ethics committee
(Ärztekammer Bremen, reference number 371).
Results
qRT-PCR analysis
Ninety samples of human fetal placenta were tested for the expression of  High-mobility
group protein AT-hook 2 (HMGA2) mRNA (table 1A and 1B). Eighty-six were collected after
an early termination of the pregnancy. Of these abortions, 64 were spontaneous, 19 were
induced (none with medical indication). In three cases, no information was available about
the type of abortion. In addition, four specimens collected after birth were examined.
The placenta samples showed a relative expression ranging from 1 to 498 (fig. 1). Overall,
there  was  a  strong  correlation  between  gestational  age  and  the  level  of  HMGA2
expression.  For  all  placenta  samples,  the  correlation  coefficient  was  0.6425
(p = 8,73*10-12)  (fig. 2).  When the analysis  was constrained to the specimens gathered
after induced abortion (IA) and after delivery (AD), the r-value was 0.8894 (p = 1,62*10-7)
(fig. 3). The samples collected after a spontaneous abortion (SA) showed a correlation
coefficient  of  0.4312  (p = 3.75*10-4)  (fig. 4).  The  relation  between  gestational  age  and
HMGA2 expression  was  found  not  to  be  significantly  different  between  these  groups
(p = 0.079, likelihood ratio test).
HMGA2 levels from samples taken during the first trimester of pregnancy  differed from
those of the joint second and third trimester highly significantly (p = 2.29*10-6, Wilcoxon
signed rank test). Using the same test, significant differences were also found within the
SA subgroup (p = 0.00938) and within the IA and AD joint subgroups (p = 1.98 * 10-5).
Taking all samples into consideration, a relatively wide ranging but overall  high level of
expression was observed up to the calendar gestational age (CGA) of 13 weeks, which
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marks the end of the first trimester. After that, the level of expression showed a decline up
to  the  CGA of  28 weeks and finally leveled  out  to  a  steady value  for  the  rest  of  the
pregnancy.  In  non-spontaneous  abortion  specimens,  the  observed  drop  was  more
pronounced and happened earlier, at around nine weeks of gestation.
Pathological  examinations of  the  specimens  after  haematoxylin  and  eosin staining
revealed a considerable contamination of maternal decidua in several samples (see also
table 1). After the immunohistochemical analysis (see also below), the decidua was found
to  be  HMGA2  negative  (data  not  shown).  Therefore,  it  seems  conceivable  that  the
presence of this tissue is the reason for low  HMGA2 expression in some of  the early
gestation samples. In two specimens,  part  of  the umbilical  cord was detected.  Human
umbilical cord blood-derived stromal cells (hUCBSCs) show high  HMGA2 expression in
culture [26,27]. Even though no data is available for fresh tissue samples, this might in part
explain the outliers with a relative high expression in later stages of the pregnancy.
Immunohistological analysis
Eleven  samples  were  investigated  for  the  presence  and  localization  of  HMGA2  via
immunohistochemical  analysis.  Overall,  the  results  from  the  immunostaining  are  in
concordance with those from the qRT-PCR, except for two relatively mild outliers. Samples
from the early gestation (eight to ten weeks CGA) showed intense signals (fig. 5A). The
strongest staining was visible in the nuclei in the stroma cells, slightly less intense signals
were  detectable  in  the  cytoplasm  of  the  trophoblast.  Samples  from  gestational  age
between 19 and 41 weeks showed only weak to very weak signals (fig. 5B). For case
number 34 (eight  weeks  CGA) the qRT-PCR suggested a relatively low expression in
comparison to other samples of the same developmental stage, but the signals for the
protein were strong (fig. 5C). For case no. 52, the measured mRNA level was above the
average value for the developmental  stage,  but  after the immunostaining only a weak
signal was visible on the slide (fig. 5D).
Discussion
To  quantify  the  amount  of  HMGA2 mRNA in  human  fetal  placentas  throughout  the
pregnancy, 90 samples encompassing calendar gestational ages (CGA) from five to 41
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weeks were investigated using quantitative real-time PCR. A highly significant correlation
was found between the level of expression of HMGA2 and the CGA. The level of HMGA2
is  high in  the early CGA samples and declines towards the end of  the first  trimester,
followed by a stable level until birth. In the samples from induced abortions and placentas
collected after birth, the HMGA2 level drops around the ninth week of CGA. Considering
all  samples,  the  decrease is  less  steep and takes place several  weeks later.  For  the
specimens collected after a spontaneous abortion, it  is conceivable that the underlying
cause of the abortion affected the development of  the placenta and the expression of
HMGA2. In addition, the CGA is less precise, because the embryo or fetus might have
died days or even weeks before abiosis of the placenta [28]. Therefore, despite a smaller
sample size, more reliable results may be obtained from the group of specimens gathered
after induced abortions and after birth.  Differences in  HMGA2 expression between the
samples at an identical specified CGA might be explained by the uncertainty of the exact
age of the embryo or fetus. In a group of 29 pregnant women, Blaas  et al.  [29] found
virtually the same growth velocities for the embryo or fetus, respectively, between seven
and twelve weeks of gestation, but considerable differences between the individuals. As a
reason, the authors discuss discrepancies between the CGA and the true gestational age
and  differences  in  development  before  week  seven  of  the  pregnancy  as  possible
explanations [29]. Following this argumentation and transferring it to the development of
the  fetal  placenta,  differences  in  HMGA2 expression  might  also  be  related  to  the
uniqueness of each placenta's development in the very early course (before week nine
CGA) of the pregnancy.
The  stable  level  of  HMGA2-expression  detected  in  samples  from  the  third  trimester
contrasts with the analysis by Rogalla et al. [11], where no HMGA2-expression was found
in  fetal  term  placenta.  A  possible  explanation  is  the  higher  sensitivity  of  qRT-PCR
compared to conventional RT-PCR.
HMGA2 is known to be participating in the proliferation of tissues by upregulation of genes
that are involved in cell  proliferation and invasion [reviewed in 2,30]. Therefore, results
presented in this study do not contradict those published by Sitras et al. [31], who tested
more than 29,000 genes, including several members of the HMG-family, but not HMGA2.
Applying microarray analysis, the authors found that genes involved in cell proliferation,
differentiation, and angiogenesis were upregulated in human placenta in the first trimester
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[31].
High HMGA2 expression coincides with the uterus being a low oxygen environment. As a
result  of  trophoblast  invasion  into  the  maternal  decidua,  spinal  arteries  are  plugged
throughout the first trimester [reviewed in 32]. Filtrated plasma enriched with secretions
from the endometrial  glands can be found in the placental intervillous space, providing
histiotrophic nutrition [33]. A low oxygen environment has been shown to be necessary for
the proliferation of cytotrophoblast cells [34,35]. Around week 7 to 8 of gestation (week 9 to
10 CGA), maternal uterine circulation to the placenta begins [36, reviewed in 37], resulting
from trophoblast  (extravillous)  invasion  of  capillaries.  This  marks  the  beginning  of  the
haemotrophic nutrition  of  the  fetus,  which  coincides  with  the  decrease  of  HMGA2
expression. 
Scheduled proliferation  and invasion of trophoblast cells are crucial  for an  undisturbed
pregnancy.  Superficial implantation of the placenta leading to poor placental and uterine
perfusion is characteristic for preeclampsia [38,39]. No known cure exists for this serious
medical condition with a maternal mortality rate of 20 % to 80 % [40], other than delivery of
the  fetus  and  placenta.  Preeclampsia  is  not  yet  fully  understood,  and  there  are  few
markers for diagnosis [41]. In combination with oxidative stress of the placenta [reviewed
in 28],  several transcription factors involved in the proliferation and differentiation of the
trophoblast have been detected to have a share in an elevated risk of preeclampsia [42-
45]. For some proteins, a significantly higher expression has been shown in early gestation
[43,44,46],  similar  to  the results  for  HMGA2.  While  symptoms  of  preeclampsia  do not
appear  before  the  20th week  of  gestation,  it  seems to  result  from earlier  changes  of
proliferation and differentiation of the trophoblast that play a key role in the implantation of
the embryo during low placental oxygenation in the first trimester [reviewed in 47]. In this
investigation, case number 90 was diagnosed as a severe form of preeclampsia, which led
to a premature delivery at the gestational age of 32 weeks (see also table 1). As expected,
the measured value for HMGA2 was distinctly within range for this late stage of pregnancy.
In case of a correlation between  HMGA2 and preeclampsia, a deviation already would
have been detectable in the first trimester, since, as discussed above, in that period of time
the proliferation and invasion of the trophoblast determines whether an elevated risk for
preeclampsia will exist. A similar situation was reported by Jeon et al. [41] for IMUP-2. The
authors suggest an association of this protein with preeclampsia, but their findings show
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no difference in expression between term patients with or without preeclampsia.
Whereas shallow infiltration of  the trophoblast  is  a  sign for  preeclampsia,  overly deep
infiltration indicates another obstetric complication: placenta accreta (including the closely
related forms of increta and percreta).  This severe complication during pregnancy has
been associated with decidual deficiency and an overinvasive trophoblast [reviewed in 48].
Placenta  accreta  accounts  for  about  1 % of  maternal  mortality  in  the  USA [49],  and
approximately 5 % of the women with this complication die [50,51]. In addition, fetal deaths
occur in almost 26 % of the cases [51]. Since the 1970s, the incidence has risen from one
in  approximately  4,000 deliveries  to  one in  333  [50,52-54].  The  reasons are  not  fully
understood, making further  investigations necessary. However, if a relation with deviant
HMGA2 expression exists, expression measured after a chorionic villus sampling might
serve  as  a  diagnostic  marker.  Since  there  is  no  definitive  method  [55] to  detect  this
complication before birth, a possible test would be of high interest.
During  the  immunohistochemical  analysis it  became apparent  that  HMGA2 is  strongly
expressed in the stroma cells of the placental villi. As expected for a transcriptional factor,
it was located in the nucleus. But, in a lesser concentration, a signal was also detected in
the cytoplasm of the trophoblast. This pattern is significantly different from that of HMGA1,
as reported by Bamberger  et al.  [56]. HMGA1 was found exclusively in the trophoblast
cells [56].  This suggests different roles for the two members of the HMGA family.  The
results from this study are in concordance with those from Genbacev et al. [19], who found
the  same  distribution  of  HMGA2  in  the  villi,  as  well  as  a  change  from  nuclear  to
cytoplasmatic  location.  Since  experiments  were  conducted  in  vitro  in  the  study  by
Genbacev et al. [19], the cell culture environment may have influenced HMGA2 expression
in  their  study.  HMGA  proteins  are  considered  nuclear  proteins  [2],  even  though
cytoplasmatic expression of HMGA1 has been reported before [56,57]. In the majority of
papers, authors only evaluated nuclear immunoreactivity for HMGA2 [58,59]. An exception
is the study by Ding et al. [60]. The authors detected cytoplasmatic HMGA2 expression in
bladder  cancer  cells  [60].  A true  signal  in  the  cytoplasm of  the  trophoblast  might  be
conceivable  due  to  the  following:  Firstly,  the  distribution  of  the  immunohistochemical
signals in the trophoblast was consistent in all samples. Secondly, the relation between the
levels  of  staining  of  the  stroma to  the  trophoblast,  which  was  identical  throughout  all
specimens. Thirdly, the manufacturer’s statement regarding the specificity of the antibody.
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And finally, the aforementioned study by Genbacev et al. [19]. As evaluated by the visual
assessment of  the staining in relation to the developmental  stage of the samples,  the
signal intensity decreased considerably with the age of the placenta, further emphasizing
the correlation between the expression of HMGA2 and the gestational age.
Conclusions
HMGA2 expression levels have been found to be high in the early fetal placenta,  with a
rapid decline around the end of the first trimester. Thus,  HMGA2 may perform essential
functions in the early development of the fetal placenta. Overall, these findings could serve
as the basis for further studies examining the role of HMGA2 in gestation. Future research
might focus on gathering information on whether a correlation of HMGA2 expression and
placenta accreta and/or preeclampsia or other placental diseases exists.
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Tables
Table 1 - Summarization of all samples investigated for the expression of HMGA2.
1A: early termination samples
RQ: relative quantification; CGA: calendar gestational age in weeks; n.a.: information not
available; percentage of decidua: sample consisted of at least 50 % decidua; umbilical
cord: sample contained a section of the umbilical cord; immunostaining: sample was used
for immunostaining with an HMGA2-specific antibody.
1B: samples collected after birth
RQ:  relative  quantification;  CGA:  calendar  gestational  age  in  weeks;  age:  age  of  the
mother  at  delivery;  sex:  sex of  the  neonate;  weight:  weight  of  the  neonate  in  grams;
C section: Caesarean section.
Table 1A:
case no. RQ CGA type of abortion note
1 140.523 7 spontaneous
2 9.902 7 spontaneous percentage of decidua
3 3.120 15 induced
4 95.469 9 spontaneous
5 46.382 10 spontaneous
6 68.581 8 spontaneous
7 36.058 8 spontaneous
8 32.201 8 induced
9 29.015 8 spontaneous
10 497.846 8 spontaneous immunostaining
11 19.692 10 spontaneous
12 89.261 9 spontaneous
13 67.173 6 induced
14 99.902 9 spontaneous
15 19.433 14 spontaneous
16 45.969 10 spontaneous
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17 49.632 7 n.a.
18 141.657 10 spontaneous
19 4.725 11 spontaneous percentage of decidua
20 13.690 9 spontaneous percentage of decidua
21 3.507 28 spontaneous
22 130.567 7 spontaneous
23 109.029 8 induced immunostaining
24 188.477 7 induced immunostaining
25 9.020 10 spontaneous
26 85.272 11 spontaneous
27 55.483 8 spontaneous
28 136.494 7 induced
29 32.358 8 induced
30 96.846 8 spontaneous
31 64.117 7 spontaneous
32 1.027 18 spontaneous
33 23.595 22 spontaneous umbilical cord
34 68.913 8 induced immunostaining
35 244.977 8 spontaneous immunostaining
36 23.640 10 spontaneous
37 39.999 11 spontaneous
38 24.045 9 spontaneous
39 2.220 20 induced
40 1.057 32 spontaneous immunostaining
41 198.117 9 spontaneous immunostaining
42 87.735 7 induced immunostaining
43 26.091 8 spontaneous
44 8.117 9 spontaneous
45 54.529 9 spontaneous
46 30.706 9 spontaneous
47 9.355 7 spontaneous percentage of decidua
48 80.126 8 spontaneous
49 21.238 10 spontaneous
50 44.867 9 spontaneous
51 1.000 7 spontaneous percentage of decidua
52 152.952 19 spontaneous immunostaining
53 63.482 7 spontaneous
54 250.892 11 spontaneous
55 15.773 7 induced percentage of decidua
59
56 160.201 7 spontaneous
57 247.132 11 spontaneous
58 92.824 7 spontaneous
59 74.893 9 spontaneous
60 162.155 7 spontaneous
61 126.681 6 induced
62 186.271 9 spontaneous
63 28.572 8 induced
64 47.861 7 induced
65 31.963 9 spontaneous
66 154.653 7 spontaneous
67 95.824 7 induced
68 31.415 9 induced
69 72.805 7 spontaneous
70 56.650 10 spontaneous
71 110.908 20 spontaneous umbilical cord
72 6.058 7 spontaneous percentage of decidua
73 22.586 14 spontaneous
74 123.656 7 induced
75 28.452 9 spontaneous
76 18.370 5 induced percentage of decidua
77 20.153 7 induced percentage of decidua
78 87.926 8 spontaneous
79 109.971 12 spontaneous
80 152.111 5 spontaneous
81 128.672 7 spontaneous
82 47.139 9 spontaneous
83 3.306 28 n.a.
84 4.502 30 n.a.
85 23.446 27 spontaneous
86 6.276 24 spontaneous
1B:
case no. RQ GA age sex weight C section note
87 1.557 38 30 m 3155 no
88 1.711 41 30 m 4250 yes immunostaining
89 1.525 38 41 m 3435 yes immunostaining
90 1.698 32 28 m 1750 yes
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Figures
Figure 1 - HMGA2 expression in relation to the gestational age.
Linear display for  HMGA2 expression, all  samples. Coloring of the rhombi denotes the
type  of  sample,  blue:  spontaneous  abortion,  red: induced  abortion,  green:  gathered
postpartum, orange: abortion, no information available on the type of abortion.
Figure  2  -  HMGA2 expression  in  relation  to  the  gestational  age  including  the  linear
regression line with 95% confidence range.
Logarithmic display for  HMGA2 expression, all samples. Coloring of the rhombi denotes
the type of sample, blue: spontaneous abortion, red: induced abortion, green: gathered
after delivery, orange: abortion, no information available on the type of abortion.
Figure 3 - HMGA2 expression in relation to the gestational age including the spline fit with
95% confidence range.
Logarithmic display for HMGA2 expression, samples collected after induced abortion and
after  birth.  Coloring of  the rhombi  denotes  the type of  sample,  red: induced abortion,
green: gathered after delivery.
Figure  4  -  HMGA2 expression  in  relation  to  the  gestational  age  including  the  linear
regression line with 95% confidence range.
Logarithmic display for HMGA2 expression, spontaneous abortion samples.
Figure 5 - Immunoreactivity for HMGA2.
As mentioned in the text, in all but two cases the qRT-PCR data was in concordance with
the interpretation of the HMGA staining. For the outliers, see (C) and (D). (A) case number
24 (seven weeks CGA) shows an intensive signal for HMGA2 and a high expression as
measured in the qRT-PCR. (B) in case no. 89 (38 weeks calendar gestational age) the
signal is barely visible, the qRT-PCR showed a very low expression. (C) case number 34
(eight weeks calendar gestational age) shows a strong signal, the measured expression
was average, (D) in case no. 52 (19 weeks calendar gestational age) the signal is weak,
the qRT-PCR data suggested a relatively high expression (see also table 1A and 1B). In all
samples with a level high enough for visual detection, HMGA2 was found in the nuclei of
the stroma cells of the villi and in the cytoplasm of the trophoblast.
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3.5. HMGA2 expression in hydatidiform moles (unpublished results)
In addition to the normal placenta tissue samples (see chapter 3.4.),  eight specimens,
initially determined as hydatidiform moles, were also tested for the expression of HMGA2.
These samples are identical to those presented in chapter 3.3.5.
The same methods as in the study above were applied with the following exceptions: All
samples  were  investigated  for  p57KIP2 expression  via  immunoblot  and  analyzed  by
fluorescence in situ hybridization (FISH). In six cases an antibody specific for HMGA2 was
used to determine the localization of the protein and for verification of the qRT-PCR data.
After  assessment  of  the  results,  two  of  the  samples  initially  diagnosed  as  partial
hydatidiform  moles  were  determined  as  hydropic  abortions,  one  turned  out  to  be  a
relatively rare PHM with paternal  triploidy (table 3).  These and the hydatidiform moles
showed a very similar pattern of  HMGA2 expression, spatially as well as concerning the
level of mRNA and protein, respectively. Quantitative real-time PCR data as well as results
from the immunostaining were very similar to the non-molar and non-hydropic placenta
samples, with overall a slightly lower level of HMGA2 (mRNA and protein), subsequently
there were no statistically significant differences.
Table 3: Analysis of hydatidiform moles and hydropic abortions.
case
no. RQ GA
initial
pathological
diagnosis
FISH
analysis
 p57KIP2
immuno-
staining
reviewed pathological
diagnosis
1 21.294 n.a. PHM triploidy positive PHM
2 38.615 9 PHM tetraploidy positive PHM w/ paternal triploidy
3 112.24 7 PHM diploidy positive HA
4 3.872 9 PHM diploidy positive HA
5 24.395 n.a. CHM diploidy negative CHM
6 34.784 9 CHM diploidy negative CHM
7 62.57 n.a. CHM diploidy negative CHM
8 35.189 6 CHM diploidy negative CHM
RQ:  relative  quantification,  HMGA2 expression;  GA:  calendar  gestational  age  in  weeks;  PHM:  partial
hydatidiform mole; CHM: complete hydatidiform mole; HA: hydropic abortion.
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Own contribution:
Study design with Jörn Bullerdiek
Execution and analysis of the study except for FISH analysis and immunostaining
Statistics with Werner Wosniok
3.5.1.  Pathological determination
Eight  samples  of  suspected  molar  pregnancies  were  investigated  (table 3).  The  initial
pathological report stated four cases as complete hydatidiform moles (CHM) and four as
partial moles (PHM). After molecular analysis, using  (FISH) and immunostaining with an
antibody specific for p57KIP2, only two samples were still declared as a PHM, the other two
were classified as hydropic abortions (HA), the four CHMs were confirmed (table 3 and
figures 1 and 2).
Figure 1: FISH analysis of the hydatidiform moles and hydropic abortions.
Representative images of the four groups determined by fluorescence in situ hybridization analysis: hydropic
abortions (HA),  complete hydatidiform moles (CHM), and partial hydatidiform moles (PHM) using probes
specific for chromosomes 1 and 6, respectively. (A): triploid PHM (case number 1, see also table 2); (B):
tetraploid PHM (case number 2); (C): diploid HA (case number 4); (D): diploid CHM (case number 8).
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Figure 2: Immunoreactivity for p57KIP2 in HA, PHM, and CHM samples.
Triploid PHM (A),  tetraploid PHM (B),  and HA (C) samples show nuclear immunoreactivity for p57 KIP2 in
stroma and cytotrophoblast  cells,  in  the CHM sample (D) only  the maternal  decidua is  positive  for  the
staining. Pictures (A) to (D) correspond to case numbers 1, 2, 4, and 6, respectively, in the investigation (see
also table 2).
3.5.2.  qRT-PCR analysis
Overall, there was no significant difference in expression of  HMGA2 between the partial
and the complete form of the hydatidiform moles (PHM-CHM: p = 0.552, Welch t-test), nor
between these and the hydropic abortions (PHM-HA: p = 0.881; CHM-HA: p = 0.791). Due
to the relatively small number of samples, the non-availability of the gestational age in
some cases and the small range of the ages, where these were available, gestational age
was not considered in this comparison.
HMGA2 expression  in  hydatidiform moles  was  not  significantly  different  from  the
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expression in normal placentas (see chapter 3.4.) from the same age window (five to ten
weeks, CGA), neither for all placentas (p = 0.0556, Welch t test) nor for the spontaneous
abortions subgroup (p = 0.0941) or joint subgroups of  specimens gathered after induced
abortion and after delivery (p = 0.0607). Only expression data from three moles could be
used for these tests. Also, when comparing the HMGA2 expression in hydatidiform mole
subgroups and the hydropic abortions with the expression in normal placentas (all cases),
no significant differences could be found (PHM: p = 0.665; CHM: p = 0.759; HA: p = 0.819,
Welch t test).
3.5.3. Immunohistological analysis
With the exception of cases 5 and 6, all samples were tested for the localization of HMGA2
protein.  Level and pattern of distribution follows closely the one from the non-hydropic
samples (see chapter 3.4.). There was no striking difference between hydropic abortions,
PHMs and CHMs, only slightly less intense signals in comparison to the non-hydropic
samples were noticeable, which is consistent with the results from the qRT-PCR (figure 3).
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Figure 3: Immunoreactivity for HMGA2 in HA, PHM, and CHM samples.
(A): triploid PHM, gestational age not available; (B): tetraploid PHM, nine weeks calendar gestational age;
(C): HA, eight weeks calendar gestational age; (D): CHM, six weeks calendar gestational age. Except for a
seemingly less intense signal the pattern of the staining is very similar to those of the non-hydropic placentas
of comparable age.  Pictures (A) to (D) correspond to sample numbers 1, 2, 3, and 8, respectively, in the
investigation (see also table 1C).
71
Results
3.6. Quantitative analysis of HMGA2 in testicular cancer
Publication IV: HMGA2 expression distinguishes between different types of
post-pubertal testicular germ cell tumours cancer (Kloth, Gottlieb et al., The 
Journal of Pathology: Clinical Research, 2015, accepted)
Human germ cell tumors can be classified into five main groups, distinguished by several
criteria  such  as  histology  and  developmental  origin  (Oosterhuis, Looijenga,  2005).
Hydatidiform moles are of type V, type II  consists of testicular seminomatous and non-
seminomatous GCTs. As mentioned before, hydatidiform moles of the uterus can lead to
the very aggressive choriocarcinoma.  This type of tumor can also develop in testicular
tissue  of  the  male.  After  elucidating  the  expression  of  HMGA2 in  context  of  the
developmental stage in the placenta, this study dealt  with the presumed differences in
expression of the gene in the subtypes of post-pubertal germ cell tumors of the testis.
qRT-PCR  data  from  59  samples  and  immunohistochemical  analysis  of  23  of  these
specimens  revealed  significant  differences  in  expression  pattern.  Seminomas  and
embryonal carcinomas showed expression levels very close to normal tissue, yolk sac
tumors  a  distinct  upregulation.  In  teratomas,  expression  varied  considerably  between
samples  and  could  also  differ  within  one  specimen.  Due  to  the  small  amount  of
choriocarcinomas,  no  final  conclusion  can  be  drawn,  but  results  indicate  a  moderate
expression. Statistical analysis revealed significant differences between the subgroups in a
linear regression analysis of real-time PCR values. Additionally, applying the Wilcoxon two-
sample rank sum test, significant differences were found between yolk sac tumors and all
other samples using data from the immunohistochemical analysis. In all cases qRT-PCR
results were in concordance with those from the immunohistochemical analysis. I t could
also be shown, that the antibody specific for HMGA2 might serve as a tool in pathological
assessment of samples in clinical application.
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Abstract
The group of postpubertal testicular germ cell tumours encompasses lesions with highly diverse differentia-
tion – seminomas, embryonal carcinomas, yolk sac tumours, teratomas and choriocarcinomas. Heterogeneous
differentiation is often present within individual tumours and the correct identification of the components is
of clinical relevance. HMGA2 re-expression has been reported in many tumours, including testicular germ cell
tumours. This is the first study investigating HMGA2 expression in a representative group of testicular germ
cell tumours with the highly sensitive method of quantitative real-time PCR as well as with immunohisto-
chemistry. The expression of HMGA2 and HPRT was measured using quantitative real-time PCR in 59 postpu-
bertal testicular germ cell tumours. Thirty specimens contained only one type of tumour and 29 were mixed
neoplasms. With the exception of choriocarcinomas, at least two pure specimens from each subgroup of tes-
ticular germ cell tumour were included. In order to validate the quantitative real-time PCR data and gather
information about the localisation of the protein, additional immunohistochemical analysis with an antibody
specific for HMGA2 was performed in 23 cases. Expression of HMGA2 in testicular germ cell tumours
depended on the histological differentiation. Seminomas and embryonal carcinomas showed no or very little
expression, whereas yolk sac tumours strongly expressed HMGA2 at the transcriptome as well as the protein
level. In teratomas, the expression varied and in choriocarcinomas the expression was moderate. In part, these
results contradict data from previous studies but HMGA2 seems to represent a novel marker to assist patho-
logical subtyping of testicular germ cell tumours. The results indicate a critical role in yolk sac tumours and
some forms of teratoma.
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Introduction
Testicular germ cell tumours (TGCTs) are relatively
rare, but in many countries they represent the most
prevalent cancer in men between 15 and 40 years of
age [1]. For unknown reasons its incidence has
increased significantly over recent decades in many
populations globally [1,2]. Nevertheless, the world-
wide frequency varies considerably between different
races and countries, with several European countries
showing the highest incidences [1,3,4]. In these
regions, up to one in 200 men is affected [3]. The
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assumed originating cells are primordial germ cells,
which undergo malignant transformation thus becom-
ing an intratubular germ cell neoplasia undifferentiated
(ITGCNU), formerly referred to as testicular intraepi-
thelial neoplasia or carcinoma in situ [reviewed in
[5,6]]. In almost all cases of ITGCNU, a TGCT with
invasive growth eventually develops [reviewed in
[7,8]]. TGCTs are divided into pure seminoma (50–
54%) and nonseminoma (ca. 46–50%) subgroups. The
latter also contains mixed tumours [9,10]. This subtyp-
ing is of clinical and prognostic relevance [10–12].
Nonseminomas display different degrees of differen-
tiation from embryonal carcinoma (EC) to mature tera-
toma and display embryonic and extraembryonic
differentiation [8,13]. Mixed forms of two or more
nonseminomas, or seminoma and nonseminoma, are
common: between 13 and 54% of tumours have been
reported to contain mixed histology [14,15]. Although
a panel of immunohistochemical biomarkers helps to
differentiate tumour subgroups, diagnosis can still be a
challenge [16].
High-mobility group AT-hook (HMGA) proteins
are small and highly charged, consisting of three
DNA-binding domains and an acidic carboxy-
terminal tail. As architectural transcription factors
they lack intrinsic transcription factor capacity but
interact with nuclear proteins and enhance or silence
transcription through changes in chromatin structure
[reviewed in [17,18]]. There are four known HMGA
proteins in humans (HMGA1a, HMGA1b, HMGA1c
and HMGA2), encoded by two genes [reviewed in
[19,20]]. High HMGA expression has been detected
at embryonic and foetal stages in mammalian tissues.
Conversely, no or only very low HMGA2 expression
has been identified in adult tissue; slightly higher lev-
els have been reported for HMGA1 in some tissues
[21–25]. The reactivation of HMGA expression has
been reported for a multitude of tumours [reviewed
in [19,26,27]. Chieffi et al. [28] found HMGA2 to be
critically involved in spermatogenesis in mice. Fur-
thermore, Di Agostino et al. [29] found that HMGA2
interacts with Nek2 in a MAPK-dependent manner in
mouse spermatogenesis. In addition to the participa-
tion in normal testicular processes, HMGA2 has also
been suggested as a marker for testicular cancer [30
and reviewed in [5,31,32]]. Franco et al. [30] showed
moderate to high expression of HMGA2 in ECs and
yolk sac tumours (YSTs).
The aim of this study was to investigate the role of
HMGA2 in postpubertal germ cell tumours of the tes-
tis. For the first time, highly sensitive quantitative
real-time PCR (qRT-PCR) has been applied in com-
bination with immunodetection, to allow more dis-
tinctive differentiation of expression levels of
HMGA2 in the subgroups. Another key aspect was
determining whether protein level could serve as a
diagnostic marker for clinical application.
Methods
Tissue samples
Formalin-fixed paraffin-embedded (FFPE) tumour tis-
sue and snap-frozen samples of normal testis were
collected at the Department of Pathology, Albertinen
Hospital, Hamburg, Germany, the Department of
Pathology, Clinical Centre Bremen-Mitte, Bremen,
Germany, and the Institute of Pathology, Elbe Clinic
Stade-Buxtehude, Germany. Additional FFPE sam-
ples were collected under the supervision of the Leib-
niz Institute for Prevention Research and
Epidemiology, Bremen, Germany. Pathological
examinations were performed after haematoxylin and
eosin staining of the samples for diagnostic purposes.
In complex cases, additional immunostaining with
antibodies specific for PLAP, OCT4, CD30, CD117,
glypican 3, AFP and b-HCG was conducted accord-
ing to the relevant pathology department’s protocol.
FFPE tissue samples from 59 postpubertal patients
with TGCT and three snap-frozen normal testis tis-
sues were examined in the study. Histology was re-
evaluated by three of the authors (B.H., T.L. and
K.B.) according to the WHO classification. Histologi-
cal subgroups were: 12 pure seminomas, three mixed
tumours with a predominant component of semi-
noma, 10 pure ECs, 13 mixed tumours with a pre-
dominant component of EC, three mixed tumours
with two equally predominant components of EC/ter-
atoma or EC/YST, two YSTs, three mixed tumours
with a predominant component of YST, six pure tera-
tomas, seven mixed tumours with a predominant
component of teratoma (see also Table 1). All sam-
ples investigated were initially taken for diagnostic
purposes and secondarily used for the present study.
Samples were deidentified before their use in this
study, in line with the rules of the Helsinki declara-
tion. The study was approved by the local ethics
committee (€Arztekammer Bremen, reference number
371).
RNA isolation
Depending on the size of the embedded tissue, FFPE
blocks were cut into six to eight sections of 5 lm for
each sample using a microtome. Total RNA isola-
tions were performed using the innuPREP Micro
RNA Kit (Analytik Jena AG, Jena, Germany) for
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Table 1. Overview of all testicular cancer samples
Sample composition (values relative to cancerous
content) Normal tissue,
Case RQ
Seminoma
(%)
EC
(%)
YST
(%)
Teratoma
(%)
CC
(%)
Undetermined
(%)
absolute
value (%) Immunohistochemistry
Patient’s
age Tumour size (cm)
HT01 7,998 0 4 4 92 0 0 75 2 32 2,8
HT02 3,617 100 0 0 0 0 0 11 2 46 6,5
HT03 9,182 0 50 10 40 0 0 70 2 18 2,7
HT04 0.763 100 0 0 0 0 0 70 2 60 1,6
HT05 0.507 100 0 0 0 0 0 90 2 35 1,3
HT06 0.901 0 100 0 0 0 0 80 2 21 2.6
HT07 3.689 0 100 0 0 0 0 70 1 29 1.9
HT08 0.312 100 0 0 0 0 0 15 2 31 4.5
HT09 130.584 0 40 40 0 0 20 25 1 39 3.5
HT10 46.510 0 0 0 70 30 0 50 1 23 6
HT11 0.865 100 0 0 0 0 0 30 2 55 1.5
HT12V 1.808 0 0 0 100 0 0 20 2 23 1.8
HT13 0.234 100 0 0 0 0 0 80 2 39 1.5
HT14 0.438 60 40 0 0 0 0 30 2 18 2
HT15 1.624 0 100 0 0 0 0 85 2 27 2
HT16 0.733 100 0 0 0 0 0 20 2 41 5.5
HT17 111.724 0 40 40 0 20 0 17 1 28 2.5
HT19 0.1* 100 0 0 0 0 0 70 1 38 2.8
HT20 1.765 100 0 0 0 0 0 90 1 50 1.5
HT22 6.922 0 100 0 0 0 0 64 1 53 1.5
HT23 1.880 0 100 0 0 0 0 90 2 35 3.5
HT24 10.833 0 4 0 96 0 0 75 2 28 0.9
HT25 1.041 75 20 5 0 0 0 56 1 20 2.8
HT26 0.681 100 0 0 0 0 0 10 2 26 3.3
HT27 0.143 100 0 0 0 0 0 30 1 39 6.5
HT28 0.322 100 0 0 0 0 0 85 2 46 2.4
HT29 0.873 0 0 0 100 0 0 15 1 21 2
HT30 74.481 0 0 20 80 0 0 38 1 66 4
HT31 17.595 0 90 5 0 5 0 43 2 37 6.5
HT32 31.621 0 60 30 0 5 5 40 2 24 8
HT33 32.310 0 80 10 0 10 0 25 2 23 4
HT34 6.474 0 96 4 0 0 0 33 2 33 1.8
HT35 0.379 0 0 75 25 0 0 38 1 35 4
HT36 50.418 0 0 100 0 0 0 26 2 36 1.5
HT37 61.414 0 80 20 0 0 0 47 2 22 3.4
HT38 1.594 0 0 5 95 0 0 20 2 35 2.6
HT39 7.565 0 90 10 0 0 0 50 2 47 3
HT40 1.403 0 100 0 0 0 0 11 1 30 n.a.
HT41 14.691 0 59 5 35 1 0 11 2 40 1.2
HT42 109.424 0 0 100 0 0 0 25 1 38 6
HT43 99.796 0 5 10 85 0 0 15 1 31 3.5
HT44 147.842 0 40 18 40 2 0 30 1 24 3.2
HT45 6.866 0 0 0 100 0 0 70 1 43 5.5
HT46 18.707 20 60 20 0 0 0 40 2 19 2.7
HT47 15.294 0 95 5 0 0 0 50 2 48 2
HT48 2.960 0 100 0 0 0 0 80 2 23 1
HT49 0.897 0 0 0 100 0 0 50 2 24 1.8
HT50 0.853 0 0 0 100 0 0 80 2 21 1.5
HT51 626.427 0 10 20 70 0 0 20 1 40 4.5
HT52 230.972 75 5 20 0 0 0 30 1 19 3
HT53 28.455 0 90 10 0 0 0 30 1 18 n.a.
HT54 130.314 0 0 95 5 0 0 41 2 43 3
HT55 13.557 0 95 5 0 0 0 22 1 23 3
HT56 6.136 0 100 0 0 0 0 29 2 29 2.1
HT57 2.301 0 0 0 100 0 0 20 2 n.a. 3.5
HT58 3.549 0 100 0 0 0 0 33 2 43 2
HT59 6.824 0 100 0 0 0 0 38 2 30 4.5
HT62 3.733 0 81 10 9 0 0 70 1 27 n.a.
HT63 119.312 0 50 50 0 0 0 26 1 38 2.5
RQ, relative quantification; HMGA2 expression, EC, embryonal carcinoma; YST, yolk sac tumour; CC, choriocarcinoma; Immunhistochemistry, sample was used in
HMGA2-specific immunhistochemistry investigation; *: set value, expression below detection level (see text for further explanation), n.a., not available.
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RNA isolation according to the manufacturer’s
instructions, with the following modifications: Lysis
of the paraffin sections preceding RNA isolation was
conducted using TLS-Lysis Solution and Proteinase
K from the innuPREP DNA Micro Kit (Analytik
Jena AG, Jena, Germany) without prior deparaffinisa-
tion. Sections were incubated for 1 h at 608C and 15
min at 808C.
cDNA-synthesis and quantitative real-time
RT-PCR
RNAs were reverse-transcribed into cDNA by M-MLV
Reverse Transcriptase (Invitrogen, Karlsruhe, Ger-
many). Real-time PCR was performed using the
Applied Biosystems 7300 sequence detection system,
software 1.2.3, according to the Taq-Man Gene Expres-
sion Assay Protocol (Applied Biosystems, Darmstadt,
Germany) in 96-well microtitre plates with a total vol-
ume of 20 ll. For the TaqMan gene expression assay
for HMGA2 (assay number Hs00171569, Applied Bio-
systems, Foster City, USA), each reaction consisted of
2 ll of cDNA reverse transcribed from 25 ng of total
RNA, 10 ll of TaqMan Universal PCR Master Mix
(Applied Biosystems), 1 ll of TaqMan assay and 7 ll
of ddH2O. For the HPRT assay, using HPRT FP and
HPRT RP primers [33], each reaction consisted of 2 ll
of cDNA reverse transcribed from 25 ng of total RNA,
10 ll of TaqMan Universal PCR Master Mix, 600 nM
(1.2 ll) of forward and reverse primers, 200 nM (0.2 ll)
of probe [33] and 5.4 ll of ddH2O. Thermal cycling
conditions were 2 min at 508C followed by 10 min at
958C, 50 cycles at 958C for 15 s and 608C for 1 min. In
each run, a negative control of previous cDNA synthesis
(missing reverse transcriptase) was included for each
sample and a nontemplate control of amplification and
a nontemplate control of previous cDNA synthesis were
included for each plate.
All testing reactions were performed in triplicate.
Considering the expression range of HMGA2, HPRT
was chosen as the endogenous control as generally
suggested by de Kok et al. [34], and as used for tes-
ticular samples by McIntyre et al. [35], Looijenga
et al. [36] and Wermann et al. [37]. The CT values
of both genes were in concordance (HMGA2:
21,914–36,006; HPRT: 23,421–37,459). As recom-
mended for FFPE samples [38] the fragment sizes
amplified by both assays were small, ranging
between 65 and 80 bp; validation of these values was
performed via gel electrophoresis of the PCR ampli-
cons (data not shown). Relative quantity (RQ) was
calculated using the ddCT method [39]. Snap frozen
tissue of normal testis was tested against FFPE from
the same sample giving highly comparable results.
Because of disposability of snap frozen normal testis
tissue, the average of three such tissues was used as
calibrator.
Immunohistochemical analysis
Slides utilized for the immunohistochemical analysis
were produced using cuts directly adjacent to those
used for the qRT-PCR investigation. Immunohisto-
chemical staining for HMGA2 (rabbit polyclonal
anti-HMGA2-P3, Biocheck, Inc., Forster City, USA)
was performed using a detection kit (DAKO Chem-
Mate; DAKO, Glostrup, Denmark) and a semiauto-
mated stainer (DAKO; TechMate) according to the
specifications of the manufacturer. For antigen
retrieval, the slides were treated in a PT Link module
(DAKO) using the EnVisionTM FLEX Target Re-
trieval Solution, low pH (DAKO). The antibody dilu-
tion used was 1:1000. Term placenta was used as a
positive control whereas negative control was per-
formed by omission of the primary antibody.
Interpretation of HMGA2 staining was done using
a Zeiss Axioplan (Carl Zeiss Microscopy GmbH,
G€ottingen, Germany) microscope. Immunoreactivity
in the nucleus was considered positive (although peri-
nuclear granulation in cytoplasm was observed occa-
sionally). In each slide, three to five high-power
fields were rated. Staining extent was scored by mul-
tiplying intensity of staining (0: no staining, 0.5: very
weak, 1: weak, 1.5: weak-moderate, 2: moderate, 2.5:
moderate-strong and 3: strong) by percentage of
stained tumour cells. Lack of available tissue was
one of the reasons why we did not perform IHC in
all cases analysed by qRT-PCR.
Statistical analysis
RQ values and immunohistochemical scores were
described by number of values, arithmetic means,
standard deviations and minimum and maximum.
Boxplots were used to summarize the distribution of
data values. Averages of immunohistochemical scores
were compared by the Wilcoxon two-sample rank
sum test. The ability of the RQ value to discriminate
between tumour subgroups was quantified for all
pairs of tumour subgroups by sensitivity and specific-
ity, obtained from Receiver-Operator-Characteristics
(ROC) analysis, thereby using a normal approxima-
tion of the empirical data. This analysis was per-
formed for all samples containing only a single type of
tumour. The relationship between lg(RQ) and the pro-
portion of tumour components – these expressed as
proportion of the total section area – was analysed by
linear regression. An intercept was omitted from the
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regression equation, because a tumour proportion of
zero is by definition associated with lg(RQ)5 0. To
allow for the logarithmic transformation of all values,
the RQ of zero observed in one case was replaced by
RQ5 0.1. This value still lies below the smallest
observed RQ value. All cases were included in this
analysis. A p value of less than 0.05 was considered
significant, a p value of less than 0.001 highly signifi-
cant. Statistical analyses were undertaken using the
SAS/STAT and SAS/GRAPH software (version 9.2 for
Windows, copyright 2002–2008 SAS Institute Inc.),
and the R software [40].
Results
qRT-PCR analysis
Fifty-nine FFPE samples of human TGCTs were
tested for the expression of HMGA2 (Table 1). Of
these tumours, 30 were pure tumours (12 seminomas,
10 ECs, two YSTs and six teratomas), 29 were mixed
GCTs. These were accompanied by three snap-frozen
normal testicular samples used for normalisation.
Overall, the samples showed an HMGA2 expression
level between 0.143 and 626.427: this relates to a
range of about 1–4381. For one sample, the expres-
sion was 0, ie the expression was below the detection
limit.
Focussing on the samples with only one tumour
subgroup, there was a clear classification between the
groups (Tables 2 and 3, Figure 1). Seminomas
showed the lowest values; with two exceptions, all
measured data were below the expression in normal
tissue. ECs and teratomas showed slightly elevated
levels, while the levels expressed by YSTs were by
far the highest. This clustering could be visualized by
aligning the samples by level of expression (Figure
2, including the mixed tumours).
To statistically validate the visual impression on
discriminatory ability, ROC analyses were performed
(Table 4). Comparisons involving YST showed a sen-
sitivity of at least 0.988 and a specificity of 0.997,
indicating a clear distinction from the other tumour
subgroups. These numbers, however, must be treated
with caution, since the YST group consisted of only
two samples. In addition to the comparison of indi-
vidual groups, seminomas were tested against all
other subgroups. This analysis indicated that semino-
mas and nonseminomas were separated moderately
well by real-time HMGA2 expression data alone with
a sensitivity of 0.912 and a specificity of 0.680.
To analyse qRT-PCR data from samples with two
or more tumour components and to accommodate for
varying percentages of normal tissue content, a linear
regression was calculated between the logarithmic
RQ and the tumour components (Table 5, Figure 3).
Comparison of observed and predicted RQ values
showed good agreement; in particular, no indication
of systematic deviation was identified. The model
achieved an adjusted coefficient of determination of
0.6625 with a p value of 1.112*10212, indicating
HMGA2 expression is dependent on the tumour sub-
group. With the exception of seminomas, each sub-
group’s contribution turned out to be significant or
highly significant (see also Table 5). There are four
values with large differences between observed and
Table 2. HMGA2 expression in pure tumours
Case RQ Type of tumour
HT02 3.617 seminoma
HT04 0.763 seminoma
HT05 0.507 seminoma
HT08 0.312 seminoma
HT11 0.865 seminoma
HT13 0.234 seminoma
HT16 0.733 seminoma
HT19 0.1* seminoma
HT20 1.765 seminoma
HT26 0.681 seminoma
HT27 0.143 seminoma
HT28 0.322 seminoma
HT06 0.901 EC
HT07 3.689 EC
HT15 1.624 EC
HT22 6.922 EC
HT23 1.880 EC
HT40 1.403 EC
HT48 2.960 EC
HT56 6.136 EC
HT58 3.549 EC
HT59 6.824 EC
HT36 50.418 YST
HT42 109.424 YST
HT12V 1.808 teratoma
HT29 0.873 teratoma
HT45 6.866 teratoma
HT49 0.897 teratoma
HT50 0.853 teratoma
HT57 2.301 teratoma
RQ, relative quantification; EC, embryonal carcinoma; YST, yolk sac tumour;
*, set value; expression below detection level (see text for further
explanation).
Table 3. HMGA2 expression in pure tumours by group
Type of tumour n Average St dev
Seminoma 12 0.904 1.004
EC 10 3.589 2.292
YST 2 79.921 41.724
Teratoma 6 2.266 2.332
n, number of cases; St dev, standard deviation; EC, embryonal carcinoma;
YST, yolk sac tumour.
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Figure 1. HMGA2 expression in pure tumours. Boxplots for the relative quantification of HMGA2 expression in TGCTs. Tumour type at
x-axis, logarithmic RQ at y-axis. Boxes contain the central 50% of all values and a bar at the position of the median, whiskers
extend to the extreme values or to 1.5 * box height, whichever is smaller. The plus sign shows the arithmetic mean.
Figure 2. Overview of all testicular cancer samples. Bar plot with RQ in the upper part, tumour composition in the lower part. Sam-
ples are arranged by level of HMGA2 expression. *: set value, expression below detection level (see text for further explanation). Col-
our code for the tumour composition: green: seminoma, blue: embryonal carcinoma, red: yolk sac tumour, orange: teratoma, purple:
choriocarcinoma, black: undetermined, grey: normal tissue.
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predicted expression. HT35 is a clear outlier, with
measured expression far below the expected value.
As the sample was composed of YST and teratoma,
taking the overall results into consideration, much
higher expression of HMGA2 had been expected.
HT51 and HT52 showed values higher than expected
considering their composition. HT19 is the sample
with the set value. In all cases, qRT-PCR data were
confirmed by immunohistochemical analysis (see
below).
Immunhistological analysis
In 23 cases, the section of the FFPE block following
those used for qRT-PCR analysis was investigated
for HMGA2 protein expression patterns. Since 14
samples contained two or more histologically dif-
ferent areas, 45 immunohistochemical scores were
gathered (Figure 4). Concordant with results from
qRT-PCR, the HMGA2 scores in seminomas were
nearly zero (mean: 0.0375). One seminoma (HT20)
showed focally strong immunoreactivity; all the
others were negative. No or very weak staining was
observed in EC components, whereas a wide range
was observed in teratoma components. There was a
tendency for immature structures to be positive,
whereas mature teratomas were negative. Exceptions
were observed, eg mature glandular structures as
goblet cells were often, but not always, strongly posi-
tive. On the other hand, primitive neuroepithelium
showed weak staining; muscular structures were neg-
ative. YST components were strongly positive. Two
exceptions were found: one YST was negative
(HT25: 5% YST, 75% seminoma, 20% EC) and one
showed weak to moderate staining (HT35: 75% YST,
25% teratoma). Both also showed unexpectedly low
HMGA2 expression by qRT-PCR. HT51 and HT52,
both displaying very high qRT-PCR values, showed
equally strong immunostaining. In choriocarcinomas
(CCs) syncytiotrophoblasts as well as cytotropho-
blasts showed weak to moderate staining (Figure 5,
Supplemental Figure 1). HMGA2 expression was
seen in 80–100% of syncytiotrophoblastic cells and
in 60% of cytotrophoblast components. As we did
not find syncytiotrophoblastic cells in our seminoma
cases we can neither confirm nor exclude HMGA2
expression in this situation. In normal tissue,
HMGA2 was detected in the cytoplasm of the sper-
matogonial cells. Nuclear expression was weak in
spermatocytes and strong in spermatids. Spermatozoa
were negative for the protein (Supplemental Figure
1).
A Wilcoxon two-sample rank sum test (Table 6)
was conducted to evaluate the separation of tumour
entities. Due to multiple testing, a corrected
a5 0.005 was used. Despite this restriction, signifi-
cant differences were detected when comparing
scores from YSTs with those from ECs and terato-
mas. Testing seminoma scores against nonseminoma
scores resulted in a significant difference in protein
level (p5 0.0154). Performing the same test with
YST values against all other scores revealed a highly
significant difference (p5 3.821*1026). Table 7
gives the results from both real-time PCR and immu-
nostaining analysis.
Discussion
An investigation using real-time PCR and immuno-
histology was performed to study the expression of
HMGA2 in all subgroups of TGCT. Overall, in com-
parison to normal tissue, seminomas showed a mar-
ginal decrease and ECs a slight upregulation. In
teratomas, the expression level was variable and
appeared to depend on cellular differentiation. CCs
(syncytiotrophblastic giant cells and to a lesser extent
cytotrophoblasts) and especially YSTs showed con-
siderably increased expression. In normal testicular
tissue, low HMGA2 expression was detected by real-
time PCR. This is most likely caused by temporarily
high expression in cells involved in spermatogenesis.
Table 5. Linear regression analysis of the relationship between
lg(RQ) and the proportion of tumour components
Tumour component Estimate Standard error t value p value
Seminoma 20.001496 0.003134 20.477 0.63502
EC 0.014816 0.002875 5.153 3.72*1026
YST 0.030189 0.004875 6.192 8.38*1028
Teratoma 0.01078 0.00327 3.297 0.00173
CC 0.06092 0.029689 2.052 0.04504
Estimate, estimate of the regression coefficient; positive values indicate an
RQ value increasing with tumour proportion, t value, test statistic for the
hypothesis ‘Coefficient is zero’; p value, level of significance; EC, embryonal
carcinoma; YST, yolk sac tumour; CC, choriocarcinoma. The model contains
no intercept, as a proportion of zero is by definition associated with
lg(RQ)5 0; data: all samples.
Table 4. ROC analysis of pure tumours
Type of tumour n Seminoma EC YST Teratoma
Seminoma 12 sens. 0.868 0.998 0.581
spec. 0.815 0.999 0.828
EC 10 sens. 0.988 0.883
spec. 0.997 0.371
YST 2 sens. 0.996
spec. 0.998
Teratoma 6 sens.
spec.
n, number of cases; sens., sensitivity; spec., specificity; EC, embryonal carci-
noma; YST, yolk sac tumour.
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Figure 3. Linear regression analysis of the relationship between lg(RQ) and the proportion of tumour components. Predicted RQ at x-
axis, observed RQ at y-axis, logarithmic scale. Each circle represents one sample. Outliers are marked by case identification (see text
for details).
Figure 4. Immunostaining score by type of tumour. Boxes contain the central 50% of all values and a bar at the position of the
median, whiskers extend to the extreme values or to 1.5* box height, whichever is smaller. The plus sign shows the arithmetic mean,
the rectangles denote outliers.
Contrary to normal tissue, no such pattern could be
detected in most seminomas and immunostaining
also showed no HMGA2 expression. Since all pure
seminomas contained a percentage of normal tissue,
it is plausible that the presence of HMGA2 mRNA
results from that portion. It is also possible that the
very low expression detected by real-time PCR is
below the threshold of immunohistochemical analy-
sis. One seminoma with relatively high expression
(>1) was also investigated using immunohistochem-
istry. Signals were restricted to one area where single
HMGA2 positive cells were scattered in between
negative seminoma cells (see Figure 5). One might
hypothesize that further transformation of seminoma
cells has taken place here. It is known that semino-
mas can progress into nonseminomas via EC
[reviewed in [6]]. As HMGA2 staining in EC was in
the range between not detectable and very weak,
another type of transformation seems more likely.
Nettersheim et al. [41] found that the seminoma cell
line TCam-2 differentiates into mixed nonseminoma-
like cell types without an intermediate step of EC
after stimulation with growth-factors TGF-b1, EGF
and FGF4. Gopalan et al. [42] also suggested a
model in which teratoma, YST and CC develop
directly from seminoma. Honecker et al. [43] found
formations of germ cells developing in nonsemino-
mas, but explicitly not in seminomas. This interesting
finding remains to be investigated further. At this
stage it can just be stated that we detected cells with
enhanced self-renewing capacity within one
seminoma.
Figure 5. Immunoreactivity for HMGA2 in different tumour subgroups. A: seminoma; B: seminoma with focal HMGA2 reactivity; C:
EC with weak granulation; D: YST, microcystic pattern; E: mature teratoma, heterogeneous staining intensity; F: CC intense staining
in syncytiotrophoblasts. Original magnifications are given.
Table 7. Summary of qRT-PCR and immunohistochemical results
Tumour
component
n
(qRT2 PCR)
n
(immunohisto)
HMGA2
expression
Seminoma 12 5 0
EC 10 14 0–1
YST 2 14 111
Teratoma 6 9 0–11
CC – 3 11*
n (qRT2 PCR), number of values from real-time PCR; n (immunohisto), num-
ber of immunohistochemical scores; 0, no expression; (1), very weak expres-
sion; 11, moderate expression; 111, strong expression; *, preliminary
deduction. Results obtained by linear regression analysis (see Table 5) were
used in addition to qRT-PCR data and immunohistochemical scores for this
summary.
Table 6. Wilcoxon two-sample test comparing the immunohisto-
chemical score by group
Type of tumour n Seminoma EC YST Teratoma CC
Seminoma 5 0.3219 0.0065 0.0223 0.0616
EC 14 0.0003 0.0054 0.0147
YST 14 0.0045 0.0544
Teratoma 9 0.3294
CC 3
n, number of values, EC, embryonal carcinoma; YST, yolk sac tumour; CC,
choriocarcinoma. In each cell, the p value is stated (2-sided t approximation
with continuity correction); a with Bonferroni correction: 0.005.
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ECs showed some variation, but always at a low to
very low level. Tumours with YST components had
a strong tendency towards high HMGA2 expression,
which was clearly confirmed by the immunohisto-
chemical analysis. Teratomas showed a heterogene-
ous pattern of expression. It seemed that positivity
depended on the type of teratoma structure. CC is the
most uncommon type of TGCT [10]. Due to the lim-
ited availability of CCs, no qRT-PCR-data from
homogeneously differentiated tumours could be gath-
ered, and results from the immunohistochemical anal-
ysis were limited. Even though the samples present
in this study showed a clear tendency, no definitive
statement can be made for this subgroup at this point.
These data partly confirm the results presented in
Franco et al. [30]. Besides immunohistology, the
authors used western blot analysis and RT-PCR.
They also detected high expression of HMGA2 in
YSTs. For seminomas, no expression was reported,
which coincides with our results from the immuno-
histochemical analysis. The residual presence of
HMGA2 expression is likely due to either the high
sensitivity of this method, or to the presence of nor-
mal cells. In three of six pure teratomas in our study,
qRT-PCR values were below one, the other three
were slightly elevated. Taking the immunohistochem-
ical analysis into account, and including mixed
tumours with a teratoma component, teratomas turned
out to be mostly positive, with only one exception of
a pure mature teratoma without any positive staining.
This is in contrast to the findings presented by
Franco et al. [30] who did not find expression of
HMGA2 in teratomas. As they did not discriminate
between immature and mature teratoma components,
direct comparison cannot be performed. Even though
it seems unlikely, it is not impossible that all of the
15 samples investigated by Franco et al. [30] were
mature forms. Results for EC could not be repro-
duced: Franco et al. [30] reported one EC with mod-
erate expression while 14 others showed high
expression. This is in clear contrast to our results, for
which we can not offer a straightforward explanation.
Murray et al. [44] also reported positive results for
EC. The authors investigated the LIN28/let-7 path-
way in malignant germ cell tumours, and found a
strongly negative correlation between LIN28 and let-
7. As a minor aspect, the study also encompassed the
analysis of the expression of HMGA2, but, due to the
limited sample size of ECs (n5 3: one postpubertal,
two paediatric), the results might not be representa-
tive for this particular group of neoplasms.
As HMGA2 is a nuclear protein, expression analy-
sis generally focuses on nuclear staining [45–49].
Nevertheless, in the present study cytoplasmic posi-
tivity was observed occasionally in teratomas and to
a lesser extent also in EC (Supplemental Figure 1).
Other researchers have made similar observations in
different tissues [47,50,51]. Taking into account these
data and using a highly specific antibody, it seems
less plausible that the cytoplasmic signal was artefac-
tual. The task of developing an approach to clarify
these findings remains.
Bearing a high mortality until the mid-1970s, today
patients with a TGCT have a 5-year survival rate of
90–95% [52–54]. The remaining deaths are mostly
due to chemoresistance of certain subgroups of
TGCT: teratomas are benign-appearing, but metasta-
ses can form in 29% [15]. Mature teratomas have lost
their embryonic features and are therefore completely
resistant to cisplatin-based chemotherapy and other
clinical treatment strategies [55]. After initial chemo-
therapy in patients with mixed TGCT with a portion
of teratoma, teratoma can be found in the residual
mass in 82% of cases [56]. CC metastasises early,
therefore a high percentage of mixed tumours show a
poor prognosis [15,57]. For several years, different
studies found an amount of >50% EC to confer a
higher risk for relapses [58]. Recently a follow-up
study showed that the any presence of EC, independ-
ently of the amount, increases the relapse risk [59].
This illustrates the importance of determining the
composition of the particular tumour. A proven set of
antibodies for determination of the subgroups exists.
Nevertheless, identification can pose a challenge for
the pathologist [16,30], and a false diagnosis rate of
4–32% has been reported [60–62].
HMGA2 expression in YST turned out to be dif-
ferent from other types of TGCTs. To a somewhat
lesser degree, immunohistochemical staining was also
positive for (immature) teratoma components and
CC. YST has a wide variety of growth patterns; it
can be difficult to differentiate from seminomas,
which is of therapeutic relevance [63]. AFP, the only
immunohistochemical marker of YST for a long
time, often shows only focal staining [15,64]. In
recent years glypican-3, SALL4 and LIN28 have
been established as diagnostic markers [15,64–68].
Glypican-3 has a higher sensitivity than AFP, but
also shows focal staining [64,69]. This was con-
firmed in the present study. In most glandular growth
patterns glypican-3 and HMGA2 showed identical
expression. Yet much more HMGA2 positivity was
observed in primitive reticular components with non-
cohesive cells (Supplemental Figure 1G, 1I). There-
fore HMGA2 staining seems to be more sensitive
than glypican-3. HMGA2 shows expression (to a
somewhat lesser degree) also in (immature) teratomas
and CCs. Ota et al. [64] also found glypican-3
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positivity in teratoma and CC. The specificity of
HMGA2 and glypican-3 is therefore comparable for
germ cell tumours. SALL4 and LIN28 are both sensi-
tive markers. SALL4 is positive in all germ cell
tumour subgroups including ITGCNU [65]. There-
fore, it cannot be used to distinguish between differ-
ent subgroups. LIN28 is sensitive for ITGCNU,
seminomas, ECs and YSTs [66]. b-HCG is an estab-
lished marker for CC, but as Lempi€ainen et al. [70]
showed recently, it can also be positive in ECs. Fur-
thermore the authors found no expression in one of
three pure CCs and two mixed TGCTs containing a
CC component.
Our data suggest that the use of a HMGA2-
specific antibody could be a sensible addition to
existing markers and potentially help to decrease the
rate of false diagnoses. A study composed of a larger
number of FFPE and fresh-frozen samples, including
a representative number of CCs, could bring this
method even closer to clinical application. In addi-
tion, investigation of the expression of HMGA2 in
ovarian and extragonadal germ cell tumours would
be of particular interest.
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SUPPLEMENTARY MATERIAL ON THE INTERNET
Additional Supporting Information may be found in the online version of this article.
Supplemental Figure 1. Examples of HMGA2 immunoreactivity in normal testis tissue and different tumour subgroups. A: normal seminiferous
tubules showing nuclear staining in spermatocytes and spermatids and weak cytoplasmic staining in spermatogonial cells, B: EC surrounded by
YST, C: mature teratoma, glandular structure, D: immature teratoma, mesenchymal appearance, E: same as D, negative glypican-3 staining
shows that no YST components are present, F: mature teratoma, glandular structures positive, muscular structures negative, G: glypican-3
staining in YST components restricted to glandular growth patterns, H: same as G, HMGA2 staining in YST is also strongly positive in primi-
tive reticular components with noncohesive cells. Original magnifications are given.
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Discussion
4. Discussion
The interaction between cells within a multi-cellular organism is controlled through the
temporally and quantitatively accurate expression of genes in each cell. Mutations in the
genome can lead to aberrant gene products and abnormal levels of proteins, which in turn
can cause diseases and syndromes. One of these diseases are lesions – hyperplasias,
and benign and malignant tumors. In 2008, in Germany alone, almost 470,000 incidences
of cancer and more than 215,000 cancer-related deaths in the population were counted
(Robert  Koch-Institut,  2012).  These  numbers  emphasize  the  need  to  understand  the
cellular processes aiming at the treatment or even prevention of diseases.
Research by Rippe  et al. (2003) uncovered a novel gene, which in a truncated form is
suspected to be a cause of the development of thyroid adenomas, and they accordingly
referred to it as thyroid adenoma associated (THADA) gene. As part of this thesis, THADA
was found to be a marker for the dedifferentiation of thyroid tissue (Kloth et al., 2011). In a
cohort  of  twelve  subgroups  of  thyroid  lesions  and  normal  tissue  samples,  the  most
dedifferentiated  anaplastic  carcinomas  showed  a  significant  lower  expression  than  all
other samples combined (Kloth et al., 2011). Furthermore, a correlation with sodium-iodide
symporter (NIS) was detected. NIS is considered a marker of thyroid differentiation (Ward
et al.,  2003;  Li,  Ain,  2010).  Therefore,  it  was concluded that  THADA may take part  in
maintaining the differentiation of follicular epithelium (Kloth et al., 2011). For treatment of
thyroid lesions the status of differentiation is of great importance, since radioiodine uptake
in tumors is no longer given when thyrocytes are progressively dedifferentiated and do not
present  iodide  transporters  on  the  basolateral  membrane  of  the  cells.  Congruously,
anaplastic  thyroid  tumors,  as  well  as  dedifferentiated  forms  of  papillary  and  follicular
neoplasms do not  respond well  to  conventional  radio-  or  chemotherapy (Vivaldi  et al.,
2009).
Thyroid-stimulating  hormone  (TSH)  is  the  main  regulator  of  thyroid  proliferation  and
differentiation  (Vassart,  Dumont,  1992).  It  mediates  its  effect  primarily  through  the
activation of the cAMP cascade (Laglia et al., 1996). NIS expression is positively regulated
via the cAMP pathway (Weiss et al., 1984). Research conducted for this thesis revealed a
cAMP response  element  (CRE)  in  THADA  (Kloth  et al.,  2011).  Therefore,  one  might
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speculate about a TSH controlled activation mechanism for THADA in the thyroid similar to
the one described for NIS.
In addition to the thyroid, NIS is also expressed in salivary glands, gastric mucosa, and the
lactating  mammary  gland  (Bizhanova,  Kopp,  2009).  Nevertheless,  it  is  considered  a
thyroid-specific  gene  (Vivaldi  et al.,  2009).  This  is  not  the  case  for  THADA,  NCBI
ESTProfileViewer shows an almost  ubiquitary expression of  THADA in  all  tissues.  For
some of them the transcripts per million (TPM)-values are zero, but in these cases the
EST pool is considerably smaller (average: 30,701 vs. 174,805 all other tissues; median:
20,430 vs. 122,252), possibly giving false negative results. Data gathered in this thesis
verify  those  results  in  principle,  even  though  some  divergences  could  be  detected.
Foremost, in all samples an expression was noticed. NCBI ESTProfileViewer marks the
thyroid as the tissue with the third highest expression in a group of 45 tissues. Only the
pharynx and  connective tissue  have  a higher TPM than detected in the thyroid.  While
testing eight different tissues, own data indicated a significantly higher expression in the
thyroid than all other tissues (Kloth et al., 2011).
Overall,  THADA expression seems to be relatively stable, in most studies undertaken as
part of this thesis it showed a variance of no more than 1 to  14.95 times. This includes
several  cell  lines,  carcinomas of  the  lung,  prostate  carcinomas,  and fetal  placenta.  In
hematological and in thyroid lesions a range of 1 to 26.31 and 1 to 45.94, respectively,
could be detected. This might be due to its yet unknown function or functions, but could
also be related to its size. In its full-length (-A1) form, THADA has a genomic size of about
365 kbp, the cDNA of its transcript spans over 6.134 bp, distributed over 38 exons, and its
protein  has  a  predicted  molecular  weight  of  220  kDa  (GenBank  accession  number:
NM_022065)  (Rippe  et al.,  2003;  Drieschner  et al.,  2007).  Arranging all  known human
RNAs and proteins by size, the above numbers put THADA in the 91st (RNA)  and 97th
(protein) percentile, respectively (Rolf Nimzyk, personal communication; refseq database,
without  predicted  RNAs/proteins,  NCBI,  September  2014).  Therefore,  a  significant
upregulation  of  the  expression  requires  a  large  amount  of  cellular  resources  and
transcription and translation take more time.
THADA variants  have  been  associated  with  several  diseases:  type 2 diabetes  (T2D),
polycystic ovary syndrome (PCOS), nonsyndromic cleft  lip  (NSCL/P),  multiple sclerosis
(MS), and certain types of cancer (see also chapter 1). Ludwig et al. (2012) suggest that
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this might be related to its large size, but that it could also reflect the effect of regulatory
elements.  Several  single nucleotide  polymorphisms (SNP) have been detected nearby
THADA and in its genomic sequence. In the last couple of years most research on THADA
focused on potential  associations  of  THADA variants  and certain  diseases.  In  several
studies no statistical significance could be reached. These sometimes conflicting results
might be caused by ethnic specificity, but might also be due to an insufficiently sized cohort
in  relation  to  the  allele  frequency  in  some  studies.  Even  though  in  some  cases  a
connection  between  the  diseases  exists,  generally  they affect  highly  different  tissues,
possibly linking  THADA to multiple cellular processes. This is illustrated by the results
presented in Cheng et al. (2011), where a low risk T2D variant was found to be the high
risk variant for colon cancer.
Interestingly,  only  one  of  the  SNPs  is  located  in  the  THADA ORF.  rs7578597,  the
aforementioned SNP associated with T2D in its major allele variant and with colon cancer
in its minor allel form, is located in a part of  THADA,  which turned out to be the most
conserved region of its protein. Drieschner et al. (2007) were able to demonstrate that the
region comprising of aa 1033 to 1415 in Homo sapiens has the highest similarity between
five vertebrates. In the minor allel form rs7578597 represents a missense mutation, an aa
with a polar functional group (threonine) becomes replaced by an aa with a hydrophobic
side chain (alanine) in the protein. One might speculate that a possible transformation of
the putative functional domain of the protein caused by this mutation could critically alter
the  biological  effect  of  THADA.  Green  et al.  (2010)  observed  a  region  of  336  kbp  in
THADA depleted of derived allels in Neanderthals. While citing Parikh  et al. (2009; see
chapter  4,  page  3),  the  authors  suggest  that  changes  in  THADA may  have  affected
aspects of energy metabolism in early modern humans (Green et al., 2010). Cardona et al.
(2014) marked THADA as a cold adaptation candidate gene. By genotyping of indigenous
Siberian populations THADA was identified as a gene with unusually rapid allele frequency
and long-range haplotype homozygosity change in the recent past (Cardona et al., 2014).
The authors relate this change to a possible advantage in energy metabolism gained by
mutations in THADA.
The conserved region reported by Drieschner  et al.  (2007)  is also the target in thyroid
adenomas when THADA becomes truncated. One of the studies undertaken for this thesis
revealed that the 3'-part of the protein has no effect on the cellular location. Using pEGFP-
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C1 and -N1 vectors and full-length (THADA-A3) and the truncated form of THADA, it could
be  shown  that  the  protein  is  located  in  the  cytoplasm  of  the  cell,  regardless  of  the
existence of the 3'-part. Therefore, it is to be expected that the effect the truncated form of
the protein exerts on the thyroid cell leading to the development of an adenoma does not
involve  a  change  of  the  localization  of  THADA.  Drieschner  et al.  (2007)  detected  a
homology  to  a  protein-protein-interaction  domain  of  the  superfamily  ARM-structure.
Therefore,  it  seems more likely that  a truncation of  THADA might  disrupt  this  putative
protein-protein interaction. If THADA is indeed involved in the death receptor pathway as
discussed by Rippe  et al.  (2003),  and  Drieschner  et al.  (2007),  this  might  explain  the
development of adenomas with a 2p21 rearrangement.
The second main aspect of this thesis was the quantitative analysis of high-mobility group
AT-hook  2 (HMGA2)  in  dedifferentiated  and  extra-embryonic  human  tissues.  Re-
expression  of  HMGA2 is  often  found  in  malignant  tumors  (reviewed  in  Cleynen,
Van de Ven, 2008; Fedele, Fusco, 2010). An upregulation in HMGA2 expression has been
associated with a progressive dedifferentiation of thyroid tumors (Belge et al., 2008). The
expression level of HMGA2 turned out to be negatively associated with the one of THADA
in the thyroid (Kloth et al., 2011). In conjunction with the positive correlation with NIS, this
finding further verifies  THADA as a marker for the dedifferentiation of thyroid epithelial
cells.  In  other  tissues this  correlation  could not  be reproduced.  Neither  in  samples  of
hematologic  diseases  (ALL,  CLL,  AML,  CML,  other  myeloproliferative  neoplasm,
malignant  lymphoma), in  carcinomas  of  the  lung  (adenocarcinoma,  squamous  cell
carcinoma)  and  the  prostate,  nor  in  fetal  placenta  specimens  a  significant  correlation
between  THADA and  HMGA2 could be detected. In thyroid cell lines results hinted at a
trend towards a positive correlation. Common to cell culture, examined cell lines derived
from benign tumors had been immortalized and it is to be expected that in vitro conditions
led to further changes of the cells in all cases. Therefore, a correlation with the tumor the
cell line originated from might not be given anymore. In no instance  THADA expression
showed a significant difference between any of the clinical subgroups. Additionally, when
comparing  THADA expression  in  lesions versus  normal  samples  of  the  same type  of
tissue, no significant differences could be detected. This could indicate that  THADA was
not involved in the degeneration of the cells in these tissues. Taken together, results might
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suggest that the biological effect of THADA in thyroid cells is different from other tissues. At
the current state of knowledge, with the exception of ß-cells in correlation with T2D as
reported by  Voight  et al.  (2010), the correlation of the biological effects of  THADA  and
HMGA2 seems to be restricted to the thyroid.
Whereas only relatively small differences in expression level of THADA could be detected
outside the thyroid,  considerable variations in  HMGA2 expression were ascertained in
extra-embryonic  and  in  dedifferentiated  tissues.  In  fetal  placenta  an  investigation
comprised of 90 samples revealed a highly significant correlation between the expression
value and the calendar gestational age (CGA) (Kloth et al., in preparation). During the first
trimester,  while the uterus is a low oxygen environment,  high  HMGA2 expression was
detected. During this period the proliferation of the placenta is higher than the one of the
fetus. This changes later with an apparent cross-over around mid-gestation (Sitras et al.,
2012). For the avoidance of several pregnancy-related complications like placenta accreta,
increta,  and percreta, and preeclampsia,  a correct  implantation of the embryo into the
uterus  is  crucial.  In  a  process  similar  to  cancerous  growth  and  invasion,  the  fetal
trophoblast  invades  the  maternal  decidua.  Normally,  this  happens  in  a  spatially  and
temporally tightly restricted manner.  In  case of  placenta accreta,  increta,  and percreta
chorionic  vili  can  invade  into  or  even  through  the  myometrium  (Belfort,  2010).  In
preeclampsia,  cytotrophoblast  differentiation  is  abnormal  and  invasion  into  the
decidualized  endometrium  is  shallow  (Genbacev  et al.,  1996).  While  the
syncytiotrophoblast  remains  mostly  epithelial,  the  extravillous  trophoblast (EVT)  goes
through the process of  epithelial-mesenchymal transition (EMT) (Vićovac,  Aplin,  1996).
Own research showed nuclear HMGA2 in stromal cells of the placental villi, and in case of
a  true  signal,  cytoplasmatic  HMGA2  in  the  trophoblast  (Kloth  et al.,  in  preparation).
Therefore, HMGA2 might not to be involved in the EMT of the EVT cells in the placenta.
Bamberger  et al.  (2003) reported the detection of HMGA1 in the EVTs. They noticed a
switch from nuclear to  cytoplasmatic expression of  HMGA1 when cytotrophoblast  cells
differentiate into EVTs. Final determination if this switch also happens for HMGA2 might be
achieved  by  separately  testing  stroma  and  trophoblast  by  qRT-PCR.  The  necessary
separation  of  the  cell  layers  could  be  performed  by  laser  dissection.  Cytoplasmatic
expression of  HMGA2 has been reported only rarely (Genbacev et al., 2011; Ding et al.,
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2014).  The  authors  do  not  give  a  possible  explanation  as  to  the  role  of  HMGA2  in
cytoplasm. For HMGA1, a role similar to HMGB1 has been discussed (Bamberger et al.,
2003). In certain cell types, HMGB1 can be secreted and after retaining its association with
the  plasma  membrane,  regulate  cell  migration  (Fages  et al.,  2000).  Bamberger  et al.
(2003) also address the ability of HMGB1 to activate extracellular proteases, which are of
importance for tissue invasion. Although no direct connection between  HMGA2 and the
above  mentioned  obstetric  complications  could  be  detected,  future  research  might
advance the knowledge on that subject using the present study as groundwork.
To elucidate if the expression of HMGA2 might serve as a marker to distinguish between
the  different  types  of  hydatidiform  moles,  non-molar  hydropic  abortions,  and  normal
pregnancies, eight such samples were tested. Hydatidiform moles are characterized by a
specific genetic setting. CHMs are usually diploid and, as first reported by Kaji and Ohama
(1977), of  androgenetic  origin.  In  the  majority  of  cases  partial  moles  are  triploid  and
diandric  (reviewed  in  Hoffner,  Surti,  2012).  These  genetic  characteristics  are  used  in
ancillary  techniques  to  support  the  pathological  assessment  (Kipp  et al.,  2010).
Differences between final results and initial diagnoses are not uncommon (Niemann et al.,
2007; Kipp et al., 2010; Sarmadi et al., 2011). The results of the present study support the
findings by Kipp et al. (2010). The macro- and microscopical determination was verified by
immunostaining with  a p57KIP2-specific  antibody and the determination of  the ploidy by
FISH. After  consultation with  the pathologist,  four  of  the samples were ascertained as
complete moles. Contrary to the initial diagnosis of partial moles, two of the four samples
could be identified as hydropic abortions, one was determined as a partial mole with a
tetraploid chromosome set. Kipp et al. (2010) presented one case with identical FISH and
p57KIP2 results, but because of the pathological analysis they favored a hydropic abortion
as the final diagnosis. Tetraploid PHMs are rare but have been described before (Surti
et al.,  1986;  Vejerslev  et al., 1987;  Lawler  et al.,  1991).  These  results  underline  the
necessity of ancillary techniques to correctly identify hydatidiform moles and non-molar
hydropic abortions and adapt the therapy accordingly.
Briese  et al. (2006) investigated CHMs for the expression of HMGA1 and found it to be
similar to that of normal placenta tissue. Own results indicate that the same is true for
HMGA2. A less intensive staining in comparison to the non-molar placenta samples at the
same gestational age, where the latter was available,  might hint at a difference, but a
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larger sample size would be necessary for clarification.
Differences in the expression level of HMGA2 have been detected between normal tissue
and benign and malignant neoplasms in a multitude of cases (reviewed in Fedele, Fusco,
2010). For a final evaluation a larger set of samples is necessary, but as a preliminary
result, the expression level of HMGA2 is not a marker to distinguish normal placentas from
hydatidiform moles and non-molar hydropic abortions nor to distinguish between CHMs
and PHMs.
Utilizing  the  highly  sensitive  method  of  real-time  PCR  in  combination  with
immunohistochemistry,  HMGA2 expression  was  investigated  on  59  samples  of  post-
pubertal testicular germ-cell tumors (TGCT). Previous studies relied on the less sensitive
RT-PCR method (Franco et al., 2008) or a very small sample pool size of three specimens
(two of which were pediatric) (Murray et al., 2013). Opposite to the study by Franco et al.,
(2008), a baseline expression could be detected in all but one case. This is probably due
to  the  higher  sensitivity  of  the  qRT-PCR  and  might  be  caused  by  the  normal  tissue
percentage of each sample. Statistical analysis revealed a separation of seminomas from
all  other  samples  by  qRT-PCR  alone  with  a  high  sensitivity  and  a  moderately  high
specificity.  Combining  the  results  from the  qRT-PCR with  the  data  gathered  after  the
immunohistochemical investigation, a highly significant difference between the YSTs and
all other specimens could be detected. Different molecular markers like OCT3/4, c-KIT,
NANOG,  and  SOX2,  amongst  others,  have  been used  to  determine the  pathogenetic
progression of this heterogeneous group of neoplasias (Honecker et al., 2006; Gopalan
et al.,  2009).  The  widely  accepted  model  marks  the  “intratubular  germ  cell  neoplasia
undifferentiated” (ITGCNU) as the initial  lesion (Oosterhuis, Looijenga, 2005; Honecker
et al., 2006; Franco et al., 2008; Gopalan et al., 2009; Chieffi, 2011; Chieffi, Chieffi, 2013).
Except for rare cases of “burned out” ITGCNUs, in all cases eventually a testicular germ
cell tumor develops (Hoei-Hansen et al., 2005). This can be a seminoma or an EC. It is
believed that through reprogramming a seminoma can be transformed into an EC, but not
an EC into a seminoma (Oosterhuis, Looijenga, 2005; Gopalan et al., 2009; Chieffi, 2011;
Chieffi,  Chieffi,  2013).  An  EC can  further  progress  into  a  teratoma,  a  YST,  or  a  CC
(Oosterhuis, Looijenga, 2005; Honecker et al., 2006; Gopalan et al., 2009; Chieffi, 2011;
Chieffi, Chieffi, 2013). This model is supported by the data from the present study. HMGA2
expression was very low to low in seminomas and ECs, and overall moderate to high in
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teratomas, YSTs and CCs. Therefore, the activation of HMGA2 seems to take place when
ECs progress into one of the other non-seminomas.  Some markers used for the above
model  are  also utilized in  histopathological  evaluation of  TGCTs, in addition to  others.
Despite these, false diagnoses up to 32 % have been reported (Segelov et al., 1993; Lee
et al., 1999; Delaney et al., 2005). Results indicate that an HMGA2-specific antibody might
be a reasonable addition to the set, possibly reducing the risk of a false diagnosis. Since
treatment and follow-up depends on correct determination, future research should further
advance this subject to bring it to clinical application.
In summary, first insights about the role of THADA in dedifferentiated thyroid tumors were
revealed. Additionally, the cytoplasmatic localization of its protein was determined. THADA
and HMGA2 have been investigated rarely together. Research undertaken as part of this
thesis elucidated a negative correlation between the expression of both genes, detected in
thyroid neoplasias. Further studies could not find this correlation in other tissues, making it
exclusive to the thyroid. Together with the high expression of THADA in this organ these
results  further  emphasize  its  role  in  the  thyroid.  High  expression  of  HMGA2 in  fetal
placenta  samples  of  low  gestational  age  reaffirms  the  role  in  early  development.  An
expression pattern deviating from the one of  HMGA1 as reported by Briese et al. (2006)
suggests a different role of the two HMGA genes in this tissue. In TGCTs a tumor subtype-
specific expression could be detected. Results strongly suggest HMGA2 as a promising
marker in the pathological determination of samples in clinical application.
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5. Summary
At  the  onset  of  this  thesis  very  little  was  known  about  THADA (thyroid  adenoma
associated).  The  gene  had  been  discovered  when  a  breakpoint  on  chromosome 2
commonly found in thyroid adenomas was narrowed down to a locus in band p21. Analysis
of the genomic structure of  THADA revealed a size of 365 kbp and 38 exons in the full-
length  form.  In  case  of  the  aforementioned  truncation  the  breakpoints  are  located  in
intron 28, thereby  translocating the 3'-end of the gene. Own research elucidated that its
protein is located in the cytoplasm, independent of the existence of the carboxy terminus
encoded by exons 29 to 38. Therefore, the development of a thyroid adenoma caused by
the truncation of  THADA does not seem to coincide with a change of the location of its
protein.
Besides  benign  adenomas,  there  are  four  main  types  of  malignant  neoplasias  of  the
thyroid. The usually relatively differentiated papillary and folliculary types of cancer are
associated  with  a  better  prognosis,  the  less  differentiated  medullary  and  anaplastic
subtypes with a lower survival rate of the patients.  THADA turned out to be a marker of
dedifferentiation of thyroid tissue. One of the cellular processes THADA may be involved in
is maintaining the differentiation of the follicular epithelium. In the thyroid  THADA might
have a particular role, since its expression turned out to be significantly higher in this organ
than in several other tissues, determined by real-time PCR. Also, only in the thyroid a
negative correlation with HMGA2 could be detected in a study analyzing the expression of
both genes on neoplastic tissue samples, cell lines and fetal placenta specimens. HMGA2
is a marker for the dedifferentiation of thyroid tissue, thereby verifying the results obtained
in the analysis of THADA expression.
HMGA2 is known to play an important role in early development. This could be confirmed
for fetal placenta samples. High qRT-PCR values were detected in samples from the first
trimester,  whereas  a  baseline  expression  could  be  observed  up  until  birth.  A protein
expression pattern diverging from the one reported for HMGA1 hints at different roles for
both  proteins.  Hydatidiform  moles  are  a  pathological  type  of  pregnancy.  They  are
characterized  by  a  usually  triploid,  diandric  (partial  hydatidiform  mole),  or  a  diploid,
paternal (complete hydatidiform mole) chromosome set. Since it is of clinical relevance to
distinguish between the subtypes, a marker would be of high interest. Due to a limited
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sample size, no final conclusion could be drawn. Results indicate no significant difference
in expression between the subtypes and between these and normal placenta specimens,
excluding HMGA2 as a marker.
While  HMGA2 is  mostly downregulated in  adult  tissues,  reexpression can be found in
several tumors, especially in malignant neoplasias. This is also the case for testicular germ
cell  tumors.  These  consist  of  seminomas,  embryonal  carcinomas,  yolk  sac  tumors,
teratomas,  and  choriocarcinomas.  Studies  preceding own  investigations  reported  an
expression level depending on the subgroup, but used the less sensitive RT-PCR or a very
small sample size. The subgroup-specific expression could not only be more distinctively
determined,  but  it  could  also  be  shown,  that  use  of  qRT-PCR  and  particularly
immunohistochemistry on HMGA2 might serve as a marker in clinical application.
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6. Zusammenfassung
Zu Anfang dieser Doktorarbeit war sehr wenig über THADA (thyroid adenoma associated)
bekannt.  Das  Gen  war  entdeckt  worden,  als  ein  in  Schilddrüsenadenomen  häufig
anzutreffender Bruchpunkt in Chromosom 2 auf einen Genlokus in Bande p21 eingegrenzt
werden konnte. Eine Analyse der genomischen Struktur von THADA ergab eine Größe von
365 kbp und 38 Exons bei  der  vollständigen Form des Gens.  Im Falle  der  erwähnten
Trunkierung ist Intron 28 betroffen, wobei das 3'-Ende des Gens transloziert wird. Eigene
Ergebnisse ergaben eine Lokalisierung des Proteins im Cytoplasma, unabhängig von der
Existenz des carboxyterminalen Endes, welches von den Exons 29 bis 38 kodiert wird.
Daher  ist  anzunehmen,  dass  es  bei  der  Trunkierung  von  THADA,  welche  zu  einer
Entstehung eines Adenoms führt, nicht zu einer Änderung der Lokalisation des Proteins
kommt.
Neben den gutartigen Adenomen gibt es vier Hauptgruppen an malignen Neoplasien der
Schilddrüse.  Die üblicherweise relativ differenzierten papillären und follikulären Formen
beinhalten  eine  bessere  Prognose,  die  weniger  differenzierten  medullären  und
anaplastischen Formen bedeuten eine geringere Überlebensrate für den Patienten.  Es
stellte  sich  heraus,  dass  THADA ein  Marker  der  Dedifferenzierung  von
Schilddrüsengewebe  ist.  Einer  der  zellulären  Prozesse,  in  die  THADA involviert  sein
könnte,  ist  die  Aufrechterhaltung  der  Differenzierung  des  follikulären  Epithels.  In  der
Schilddrüse könnte  THADA eine besondere Rolle spielen, da sich in diesem Organ die
Genexpression  als  signifikant  höher  als  in  mehreren  anderen  Geweben  herausstellte.
Dazu wurde nur in  der Schilddrüse eine negative Korrelation mit  HMGA2 als Teil einer
Studie  detektiert,  bei  der  die  Expression  von  beiden  Genen  in  neoplastischen
Gewebeproben, Zelllinien und fetalen Plazenta-Proben gemessen wurde.  HMGA2 ist ein
Marker der Dedifferenzierung von Schilddrüsengewebe, wodurch die Ergebnisse, welche
bei der Untersuchung an THADA gewonnen werden konnten, verifiziert wurden.
Von HMGA2 ist bekannt, dass es eine wichtige Rolle in der Frühentwicklung spielt. Dieses
konnte  für  fetale  Plazenta-Proben  bestätigt  werden.  Hohe  qRT-PCR-Werte  wurden  in
Proben  aus  dem  ersten  Trimester  gefunden,  wohingegen  im  weiteren
Schwangerschaftsverlauf bis zur Geburt eine Grundexpression feststellbar war. Eine von
der  berichteten  Protein-Expression  von  HMGA1  abweichende  Expression  deutet auf
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unterschiedliche Rollen der beiden Proteine hin. Blasenmolen stellen eine pathologische
Form  der  Schwangerschaft  dar.  Sie  sind  durch  einen  typischerweise  triploiden,
diandrischen (partielle Blasenmole), oder durch einen diploiden, paternalen (vollständige
Blasenmole)  Chromosomensatz  gekennzeichnet.  Da  es  von  klinischer  Relevanz  ist
zwischen den Subtypen unterscheiden zu können, wäre ein Marker von großem Interesse.
Aufgrund  eines  begrenzten  Probensatzes  konnte  keine  endgültige  Schlussfolgerung
gezogen  werden.  Die  Ergebnisse  deuten  auf  keinen  signifikanten  Unterschied  der
Expression zwischen den Subtypen und zwischen diesen und normalen Plazenta-Proben
hin, welches HMGA2 als Marker ausschließt.
Während  HMGA2 in  adulten  Geweben  weitestgehend  herunter  reguliert  ist,  kann  in
verschiedenen  Tumoren  eine  Reexpression  gefunden  werden.  Dies  ist  auch  bei
testikulären  Keimzelltumoren  der  Fall.  Diese  setzen  sich  aus  Seminomen,
Embryonalkarzinomen, Dottersacktumoren und Chorionkarzinomen zusammen. Studien,
die  eigenen  Untersuchungen  voraus  gingen,  berichteten  von  einer  Abhängigkeit  des
Expressionsniveaus vom Subtyp, verwendeten allerdings die weniger sensitive RT-PCR
oder einen sehr kleinen Probenumfang. Es konnte nicht nur die Subgruppen-spezifische
Expression in deutlicherem Maße bestimmt werden, sondern auch gezeigt werden, dass
qRT-PCR und insbesondere Immunhistochemie an HMGA2 als Marker in der klinischen
Anwendung Einsatz finden könnte.
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10. Appendix
The following tables 4-8 contain the expression data for  THADA and  HMGA2  used to
determine if a suspected correlation between the two genes exists in tissues other than the
thyroid (see section 3.3).
Table 4: THADA and HMGA2 expression in cell cultures.
sample THADA RQ HMGA2 RQ tissue
S40.2/TSV40 5.463 236.123 thyroid adenoma
S121/TSV40 2.582 n.a. thyroid adenoma
S141.2/TSV40 5.130 n.a. thyroid adenoma
S211/TSV40 3.722 194.444 thyroid adenoma
S325/TSV40 3.976 n.a. thyroid adenoma
S533/TSV40 3.106 n.a. thyroid adenoma
FTC133 5.994 160.990 follicular thyroid carcinoma
FTC238 6.054 185.396 follicular thyroid carcinoma
HTH74 7.079 n.a. anaplastic thyroid carcinoma
S277 14.950 270.937 anaplastic thyroid carcinoma
Jurkat 1.000 0.010 T-cell leukemia
SupT1 6.160 475.736 T-cell leukemia
Myco 1T 8.615 0.629 pleomorphic adenoma of the salivary glands
Li14/TSV40 3.301 237.012 lipoma
Fi primary cells 3.536 n.a. skin fibroblasts
HMGA2 expression data was kindly provided by Anke Meyer (Center for Human Genetics, University of
Bremen). RQ: relative quantification; tissue: tissue (tumor type) cell line deriving from; n.a.: not available.
Table 5: THADA and HMGA2 expression in carcinomas of the lung.
sample type histology age grade stage THADA RQ HMGA2 AQ
A1 cancer
ac 61 G1 1B
2.072 385,069
A1n normal 1.689 7,519
A2 cancer
ac 73 G3 3A
2.579 7,153
A2n normal 2.283 289
A3 cancer
ac 70 G3 3A
4.806 8,320,000
A3n normal 1.000 525,947
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sample type histology age grade stage THADA RQ HMGA2 AQ
A4 cancer
ac 62 G2 2B
1.528 616,236
A4n normal 2.742 69,511
A7 cancer
ac 63 G3 3A
1.489 5,422
A7n normal 1.750 1,664
A8 cancer
ac n.a. G2 n.a.
4.394 123,801
A8n normal 3.174 8,203
A9 cancer
ac 57 G3 2A
2.723 127,197
A9n normal 2.633 2,331
A10 cancer
ac 61 G2 4
2.338 16,470
A10n normal 1.830 2,542
A11 cancer
ac 61 G3 3A
1.721 5,584,977
A11n normal 4.813 192,350
P1 cancer
sc 70 G2 2B
3.151 3,528,705
P1n normal 1.462 337,270
P2 cancer
sc n.a. G2 2B
5.165 7,778,535
P2n normal 2.395 8,954
P3 cancer
sc 64 G3 1A
1.472 362,274
P3n normal 2.426 8,611
P4 cancer
sc 62 G1 3B
4.182 13,749,450
P4n normal 2.285 55,266
P5 cancer
sc 62 G2 2B
2.126 164,355
P5n normal 2.619 15,855
P6 cancer
sc 74 G1 3B
1.725 1,321,792
P6n normal 2.212 11,754
P7 cancer
sc 69 G1 1B
3.663 11,478,720
P7n normal 1.989 14,884
P8 cancer
sc 62 G3 2B
2.749 31,432
P8n normal 1.915 5,802
P9 cancer
sc 59 G1 2B
2.445 1,243,528
P9n normal 1.910 4,423
HMGA2 expression data (absolute quantification) was kindly provided by Britta Meyer (Center for Human
Genetics, University of Bremen). Type: type of tissue, cancer or corresponding normal tissue; RQ: relative
quantification; AQ: absolute quantification, number of transcripts/250 ng total RNA; n.a.: not available.
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Table 6: THADA and HMGA2 expression in prostate carcinomas.
sample Gleason grading Gleason score THADA RQ HMGA2 RQ
P01 3+3 6 1 6.01
P02 2+3 5 1.142 4.95
P03 4+3 7 1.057 4.41
P04 4+3 7 1.309 1.00
P05 5+4 9 3.047 20.69
P06 4+4 8 2.048 3.56
P07 4+4 8 1.122 290.11
P08 3+3 6 2.805 n.a.
P09 3+3 6 2.119 7.04
P10 5+4 9 1.112 4.03
P11 4+5 9 1.383 148.71
P12 3+3 6 2.205 7.61
P13 4+4 8 1.412 5.61
P14 4+3 7 3.312 16.50
P15 4+4 8 1.664 41.61
HMGA2 expression data was kindly provided by Anke Meyer  (Center for Human Genetics, University of
Bremen). RQ: relative quantification; n.a.: not available.
Table 7: THADA and HMGA2 expression in hematologic diseases including outside 
controls.
sample THADA RQ HMGA2 AQ classification therapy age cell no.
30 1.533 n.a. normal blood - n.a. n.a.
31 0.703 n.a. normal blood - n.a. n.a.
32 1.232 n.a. normal blood - n.a. n.a.
33 0.904 n.a. normal blood - n.a. n.a.
34 0.860 n.a. normal blood - n.a. n.a.
35 0.942 n.a. normal blood - n.a. n.a.
36 0.826 n.a. normal blood - n.a. n.a.
B03 1.287 16,431 CLL 1 59 30.9
B18 2.101 4,298 CLL 1 65 13.2
B54 0.765 7,112 CLL 2 57 5
B32 0.636 388,139 ALL 0 39 4.8
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sample THADA RQ HMGA2 AQ classification therapy age cell no.
B01 0.899 13,583 ALL 1 29 11.1
B07 0.604 13,583 ALL 1 29 9.2
B06 1.847 10,937 ALL 2 44 5.8
B17 0.134 36,873 ALL 0 61 2.9
B35 0.387 94,313 ALL 1 67 2.5
B08 0.411 21,306 ALL 2 34 7
B25 1.052 6,037 CML 1 68 5.5
B05 0.549 29,062 CML 1 61 8.9
B14 1.109 49,718 CML 1 66 13.1
B57 0.948 12,949 CML 1 68 6.5
B60 0.369 7,918 CML 1 54 3
B22 2.250 n.a. CML 1 64 40
B33 1.034 2,686,810 AML 0 67 1.2
B28 0.673 9,045 AML 0 96 10
B62 0.639 6,708 AML 2 51 8
B26 1.810 387,910 AML 0 68 9.6
B15 0.483 11,462 AML 1 66 5.8
B29 0.336 9,619 AML 0 69 2.2
B36 1.101 7,887 AML 0 44 17
B53 0.281 11,242 AML 0 74 1.3
B04 1.374 15,297 AML 2 56 5.9
B37 0.430 9,331 AML 2 68 6.2
B34 0.362 84,906 AML 0 80 2.9
B31 1.968 2,228,310 AML 0 71 1.8
B16 0.551 53,298 AML 0 69 1.4
B52 2.955 598,278 AML 1 85 70
B21 3.512 3,936 AML 1 84 2.2
B13 0.660 8,604 other myeloproliferative neoplasm 1 70 4.5
B24 0.373 9,423 other myeloproliferative neoplasm 0 72 2.4
B58 0.642 43,743 other myeloproliferative neoplasm 1 75 76.1
B66 0.997 3,399 other myeloproliferative neoplasm 1 57 3.4
B68 0.755 10,150 other myeloproliferative neoplasm 1 74 4.1
B46 1.251 5,396 other myeloproliferative neoplasm 1 61 3.8
B65 0.435 18,359 other myeloproliferative neoplasm 1 48 3
B50 0.871 5,369 other myeloproliferative neoplasm 0 57 11.5
B02 0.456 10,492 malignant lymphoma 1 66 1.7
B20 1.710 605,254 malignant lymphoma 2 57 4.6
B23 0.999 2,767 malignant lymphoma 2 57 5.1
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sample THADA RQ HMGA2 AQ classification therapy age cell no.
B40 1.159 1,451 malignant lymphoma 2 57 n.a.
B49 0.462 7,236 malignant lymphoma 2 62 3.7
B43 0.673 10,632 malignant lymphoma 0 68 6.1
B47 0.989 6,821 malignant lymphoma 0 83 9.8
B64 0.815 2,870 malignant lymphoma 2 42 9.1
B41 1.736 4,444 malignant lymphoma 0 24 12.4
B42 1.321 7,712 malignant lymphoma n.a. 37 n.a.
B45 0.522 6,291 other neoplasia 1 68 8
B67 1.104 4,123 other neoplasia 0 48 6.2
B44 0.802 5,469 systemic lupus erythematosus 1 58 8.3
B59 0.714 9,476 systemic lupus erythematosus 1 59 4
B55 1.401 4,737 Takayasu syndrome 1 34 7.2
B61 0.487 6,226 dermatomyositis 1 66 4.2
B63 1.169 6,878 amyloidosis of the kidney 1 65 6.4
HMGA2 expression data (absolute quantification) was kindly provided by Britta Meyer (Center for Human
Genetics,  University  of  Bremen).  RQ:  relative  quantification;  AQ:  absolute  quantification,  number  of
transcripts/250 ng total RNA; therapy: phase of therapy, blood sample taken 0: before, 1: during: 2: after
therapy; cell no.: cell number in Giga/l; n.a.: not available.
Table 8: THADA and HMGA2 expression in fetal placenta.
sample THADA RQ HMGA2 RQ classification CGA
P001 11.673 140.523 SA 7
P002 4.681 9.902 SA 7
P003 3.106 3.120 AR 15
P004 4.480 95.469 SA 9
P005 9.035 46.382 SA 10
P006 4.697 68.581 SA 8
P007 3.602 36.058 SA 8
P008 3.756 32.201 AR 8
P009 6.744 29.015 SA 8
P010 8.260 497.846 SA 8
P011 3.386 19.692 SA 10
P012 4.787 89.261 SA 9
P013 4.461 67.173 AR 6
P014 7.197 99.902 SA 9
P015 8.130 19.433 SA 14
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sample THADA RQ HMGA2 RQ classification CGA
P016 6.236 45.969 SA 10
P017 4.831 49.632 n.a. 7
P018 5.614 141.657 SA 10
P019 3.626 4.725 SA 11
P020 4.787 13.690 SA 9
P021 5.945 3.507 SA 28
P022 7.689 48.989 SA n.a.
P023 7.386 130.567 SA 7
P024 7.811 109.029 AR 8
P025 7.760 188.477 AR 7
P026 7.232 9.020 SA 10
P027 5.717 85.272 SA 11
P028 5.697 55.483 SA 8
P029 4.587 136.494 AR 7
P030 6.689 32.358 AR 8
P031 10.319 96.846 SA 8
P032 8.720 64.117 SA 7
P033 3.949 1.027 SA 18
P034 10.295 23.595 SA 22
P035 5.551 68.913 AR 8
P036 4.295 244.977 SA 8
P037 6.748 23.640 SA 10
P038 6.969 39.999 SA 11
P039 5.709 24.045 SA 9
P040 5.051 2.220 AR 20
P041 11.484 1.057 SA 32
P042 4.815 198.117 SA 9
P043 9.984 126.931 n.a. n.a.
P044 7.177 87.735 AR 7
P045 7.469 26.091 SA 8
P046 5.248 8.117 SA 9
P047 7.331 54.529 SA 9
P048 8.654 30.706 SA 9
P049 3.626 9.355 SA 7
P050 5.280 80.126 SA 8
P051 7.949 21.238 SA 10
P052 5.354 44.867 SA 9
P053 3.937 1.000 SA 7
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sample THADA RQ HMGA2 RQ classification CGA
P054 8.890 123.155 AR n.a.
P055 4.059 152.952 SA 19
P056 6.165 8.690 AR n.a.
P057 6.976 27.170 n.a. n.a.
P058 5.886 63.482 SA 7
P059 8.346 250.892 SA 11
P060 5.476 15.773 AR 7
P061 13.142 160.201 SA 7
P062 10.787 247.132 SA 11
P063 10.366 92.824 SA 7
P064 9.752 74.893 SA 9
P065 5.953 162.155 SA 7
P066 5.886 126.681 AR 6
P067 7.799 186.271 SA 9
P068 4.902 28.572 AR 8
P069 5.264 47.861 AR 7
P070 7.583 31.963 SA 9
P071 7.461 154.653 SA 7
P072 6.169 95.824 AR 7
P073 5.646 31.415 AR 9
P074 6.437 72.805 SA 7
P075 8.984 56.650 SA 10
P076 1.000 110.908 SA 20
P077 5.626 6.058 SA 7
P078 8.197 22.586 SA 14
P079 9.102 179.214 SA n.a.
P080 6.697 123.656 AR 7
P081 4.252 28.452 SA 9
P082 3.465 18.370 AR 5
P083 5.228 20.153 AR 7
P084 3.039 87.926 SA 8
P085 7.417 109.971 SA 12
P086 5.394 152.111 SA 5
P087 8.787 128.672 SA 7
P088 6.240 47.139 SA 9
P089 7.433 1.782 n.a. n.a.
P090 9.606 3.306 n.a. 28
P091 13.047 1.865 n.a. n.a.
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sample THADA RQ HMGA2 RQ classification CGA
P092 3.453 4.502 n.a. 30
P093 7.724 23.446 SA 27
P094 6.823 6.276 SA 24
PT002 9.122 1.557 NB 38
PT003 9.039 1.711 NB 41
PT004 6.366 1.525 NB 38
PT006 8.118 1.698 NB 32
PM1 6.937 21.294 n.a., PHM n.a.
PM2 7.689 38.615 SA, PHM 9
PM3 8.496 112.240 SA, HA 7
PM4 6.020 3.872 SA, HA 9
BM1 7.732 24.395 n.a., CHM n.a.
BM2 5.142 34.784 n.a., CHM 9
BM3 6.161 62.570 n.a., CHM n.a.
BM4 6.445 35.189 SA, CHM 6
RQ: relative quantification; CGA: calendar gestational age;  SA: spontaneous abortion, AR: abruptio; NB:
normal birth; PHM: partial hydatidiform mole; HA: hydropic abortion; CHM: complete hydatidiform mole; n.a.:
not available.
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